<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">medRxiv</journal-id><journal-id journal-id-type="pmc-domain-id">3854</journal-id><journal-id journal-id-type="pmc-domain">medrxiv</journal-id><journal-id journal-id-type="publisher-id">MEDRXIV</journal-id><journal-title-group><journal-title>medRxiv</journal-title></journal-title-group><publisher><publisher-name>Cold Spring Harbor Laboratory Preprints</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12772651</article-id><article-id pub-id-type="pmcid-ver">PMC12772651.1</article-id><article-id pub-id-type="pmcaid">12772651</article-id><article-id pub-id-type="pmcaiid">12772651</article-id><article-id pub-id-type="pmid">41503465</article-id><article-id pub-id-type="doi">10.64898/2025.12.30.25343229</article-id><article-version-alternatives><article-version article-version-type="pmc-version">1</article-version><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Individuals whose phenotype deviates from genetic expectation defined by common variation are enriched for rare damaging variants in genes that cause rare disease</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4681-374X</contrib-id><name name-style="western"><surname>Baya</surname><given-names initials="NA">Nikolas A.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="CR1" ref-type="corresp">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0312-209X</contrib-id><name name-style="western"><surname>Lassen</surname><given-names initials="FH">Frederik H.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-7417-1393</contrib-id><name name-style="western"><surname>Hill</surname><given-names initials="B">Barney</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0001-7680-1208</contrib-id><name name-style="western"><surname>Venkatesh</surname><given-names initials="SS">Samvida S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-2764-6787</contrib-id><name name-style="western"><surname>Currant</surname><given-names initials="H">Hannah</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-4903-9374</contrib-id><name name-style="western"><surname>Lindgren</surname><given-names initials="CM">Cecilia M.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A5" ref-type="aff">5</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="FN1" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0824-0047</contrib-id><name name-style="western"><surname>Palmer</surname><given-names initials="DS">Duncan S.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A6" ref-type="aff">6</xref><xref rid="A7" ref-type="aff">7</xref><xref rid="FN1" ref-type="author-notes">#</xref><xref rid="CR1" ref-type="corresp">&#8224;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom</aff><aff id="A2"><label>2</label>Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom</aff><aff id="A3"><label>3</label>Department of Statistics, University of Oxford, Oxford, United Kingdom</aff><aff id="A4"><label>4</label>Nuffield Department of Population Health, Medical Sciences Division, University of Oxford, Oxford, United Kingdom</aff><aff id="A5"><label>5</label>Nuffield Department of Women&#8217;s and Reproductive Health, Medical Sciences Division, University of Oxford, United Kingdom</aff><aff id="A6"><label>6</label>Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America</aff><aff id="A7"><label>7</label>The Pioneer Centre for SMARTbiomed, Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, United Kingdom</aff><author-notes><fn fn-type="other" id="FN1"><label>#</label><p id="P1">Senior authors</p></fn><corresp id="CR1"><label>&#8224;</label>Corresponding authors: <email>nikolasbaya@gmail.com</email>, <email>duncan.stuart.palmer@gmail.com</email></corresp><corresp id="CR2"><bold>Correspondence</bold>: Correspondence, including requests for further information and resources, should be directed to NAB (<email>nikolasbaya@gmail.com</email>) and DSP (<email>duncan.stuart.palmer@gmail.com</email>).</corresp></author-notes><pub-date pub-type="epub"><day>31</day><month>12</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">504273</issue-id><elocation-id>2025.12.30.25343229</elocation-id><pub-history><event event-type="pmc-release"><date><day>06</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>07</day><month>01</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-01-08 15:25:13.993"><day>08</day><month>01</month><year>2026</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution-NonCommercial 4.0 International License</ext-link>, which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihpp-2025.12.30.25343229v1.pdf"/><self-uri content-type="pdf">nihpp-2025.12.30.25343229.pdf</self-uri><abstract id="ABS1"><p id="P4">Polygenic scores (PGS) predict complex traits and stratify disease risk but often fail to fully capture individual-level variation. &#8220;Misaligned&#8221; individuals, whose observed phenotypes deviate from their genetically expected values based on polygenic scores (PGS), provide a powerful model for identifying factors beyond common-variant effects, including additional genetic factors. Here, we apply misalignment classification and enrichment testing frameworks to seven continuous and three dichotomous traits, assessing whether misaligned individuals in the UK Biobank are enriched for rare (minor allele frequency (MAF) &lt; 0.1%) damaging genetic variation. We identify significant enrichment (false discovery rate (FDR)-adjusted <italic toggle="yes">P</italic> &lt; 0.05) of predicted loss-of-function (pLoF) variants in <italic toggle="yes">COPB2</italic> and <italic toggle="yes">GORAB</italic> among individuals misaligned for lower-than-expected bone mineral density. We refine previously observed grouped-gene enrichment in individuals with misaligned stature to the single-gene level: shorter-than-expected individuals are enriched for pLoF variants in <italic toggle="yes">ACAN</italic> and <italic toggle="yes">IGF1</italic>, and taller-than-expected individuals are enriched for predicted damaging missense in <italic toggle="yes">FBN1</italic>. Using an individual&#8217;s misalignment classification as a phenotype, we perform an exome-wide scan across seven traits, resulting in 74 FDR-significant genes. We identify <italic toggle="yes">KANK1</italic> as a gene associated with later age at menopause, potentially protective against primary ovarian insufficiency. For dichotomous disease status traits, we demonstrate evidence for the liability threshold model in the context of counteracting conditionally-orthogonal common and rare variant pathogenic/protective effects. Among individuals diagnosed with type 2 diabetes, carriers of rare pathogenic pLoF variants in <italic toggle="yes">HNF1A</italic> and <italic toggle="yes">HNF4A</italic> had significantly lower polygenic risk than non-carriers (FDR-adjusted one-sided <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt; 5 &#215; 10<sup>&#8722;3</sup>). We also show that coronary artery disease controls carrying rare protective pLoF variants in <italic toggle="yes">ANGPTL3</italic> had nominally higher polygenic risk (one-sided <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> = 0.03) than non-carriers. This study highlights the power of misalignment-based analyses in complex continuous phenotypes and disease, with the potential to validate known genetic contributors to traits and identify novel genes. This work paves the way for better molecular diagnoses and targeted therapeutic discovery.</p></abstract><funding-group><funding-statement>NAB is supported by the Pembroke College Oxford-Bendich Graduate Scholarship, the Clarendon Fund, and Wellcome Trust Grant Number 224890/Z/21/Z. SSV is supported by the Rhodes Scholarships, Clarendon Fund, and the Medical Sciences Doctoral Training Centre at the University of Oxford. FHL is supported by the Wellcome Trust (award 224894/Z/21/Z) and the Medical Sciences Doctoral Training Centre at the University of Oxford. CML is supported by the Li Ka Shing Foundation, NIHR Oxford Biomedical Research Centre, Oxford, NIH (1P50HD104224-01), Gates Foundation (INV-024200). This research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z, and Wellcome Trust Residual award (221782/Z/20/Z) with additional support from the NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. HC is supported by Wellcome (318918/Z/24/Z) and NIH (1P50HD104224-01).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>Introduction</title><p id="P5">Modeling <italic toggle="yes">how</italic> an individual develops disease is key to preventing disease. One approach to modeling genetic disease risk is the liability threshold model<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup>. This model assumes a continuous &#8220;liability&#8221; for disease, comprised of genetic and environmental contributions<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. An individual develops disease if their liability exceeds a certain threshold. The genetic risk portion of this liability can be separated into risk contributed by common variants and rare variants for a heritable trait<sup><xref rid="R3" ref-type="bibr">3</xref></sup> (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><p id="P6">One way to quantify the common-variant genetic component of a phenotype is with polygenic scores (PGS)<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R5" ref-type="bibr">5</xref></sup>. PGS have transformed the study of complex traits by enabling the prediction of phenotypes and disease risk based on the aggregate contribution of common genetic variation<sup><xref rid="R6" ref-type="bibr">6</xref>&#8211;<xref rid="R9" ref-type="bibr">9</xref></sup>. However, given the many other contributors to phenotypic variability in the population, assessing how an individual&#8217;s observed phenotype deviates from expectation based on their PGS could refine signal for other components (e.g. rare variants, environmental effects) and improve power in association studies. For example, adjusting for PGS has been demonstrated to improve power in rare variant association analyses<sup><xref rid="R10" ref-type="bibr">10</xref></sup>.</p><p id="P7">There are other applications for this notion of divergence from the genetically-expected phenotype measured by aggregating common-variant effects. Under a liability threshold model, individuals diagnosed with disease but with low common-variant risk may be expected to have other independent components of risk causing them to cross the liability threshold. This is consistent with recent literature showing that diagnosed individuals with low common-variant risk are more likely to carry rare pathogenic variants<sup><xref rid="R11" ref-type="bibr">11</xref></sup> or have a monogenic diagnosis<sup><xref rid="R12" ref-type="bibr">12</xref></sup>. There are many other recent examples of work involving the interplay of polygenic and monogenic risk, especially demonstrating how common-variant polygenic risk can modulate the penetrance or expressivity of monogenic risk variants. Disorders for which this has been demonstrated include breast cancer<sup><xref rid="R13" ref-type="bibr">13</xref>&#8211;<xref rid="R15" ref-type="bibr">15</xref></sup>, Huntington&#8217;s disease<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup>, glaucoma<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup>, familial hypercholesterolaemia (FH)<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup>, obesity<sup><xref rid="R20" ref-type="bibr">20</xref></sup>, developmental disorders<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup>, chronic kidney disease<sup><xref rid="R23" ref-type="bibr">23</xref></sup>, and schizophrenia<sup><xref rid="R24" ref-type="bibr">24</xref></sup>.</p><p id="P8">Here, we test for enrichment of rare (MAF &lt; 0.1%) deleterious variants in UK Biobank (UKB) individuals who deviate from their genetically-expected phenotype based on PGS (<xref rid="F1" ref-type="fig">Figure 1</xref>), using common-variant PGS calculated by genomics PLC<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and provided through UKB. We assess seven continuous traits (standing height, low-density lipoprotein cholesterol (LDL-C), body mass index (BMI), glycated haemoglobin (HbA1c), bone mineral density (BMD), intraocular pressure (IOP), and age at menopause (AAM)) and three dichotomous disease status traits (type 2 diabetes (T2D), coronary artery disease (CAD), and osteoporosis (OP)) in our analysis. These traits were selected due to having polygenic and monogenic components of heritability. The selection of dichotomous traits was also motivated by the availability of their corresponding continuous &#8220;liability&#8221; traits (HbA1c for T2D, LDL-C for CAD, BMD for OP), which enabled us to use many of the same gene sets between traits. For continuous traits, we test for rare putatively deleterious variation in individuals with misaligned phenotypes using an existing framework<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, and develop a new testing framework to enable the analysis of dichotomous traits.</p><p id="P9">We build the scope of our investigation in stages. We begin our enrichment testing in a small set of &#8220;canonical&#8221; genes, curated for each trait, linked to monogenic disorders or strongly associated with the trait. In this context, we have a strong prior for misaligned individuals to show enrichment for deleterious rare variation, given previous work in a smaller subset of UKB<sup><xref rid="R26" ref-type="bibr">26</xref></sup>.</p><p id="P10">We then expand our analysis to a larger set of genes considered to be of diagnostic grade for rare disorders related to our selected traits, taken from the Genomics England gene panel<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. This approach allows us to test many more genes than the canonical genes while maintaining a hypothesis of rare genetic disorder enrichment in misaligned individuals.</p><p id="P11">Finally, we explore whether this framework of testing for deleterious variant enrichment in misaligned individuals can be re-appropriated for discovery of novel pathogenic or protective genetic effects. To do this, we treat misalignment as the trait of interest and perform gene-level association testing of protective and pathogenic damaging rare variation across the exome.</p><p id="P12">Altogether this study comprises the largest investigation of phenotype deviation to date, providing further evidence for models of counteracting pathogenic/protective common and rare variant effects.</p></sec><sec id="S2"><title>Methods</title><sec id="S3"><title>Exome sequencing data quality control and assigning population labels</title><p id="P13">We performed sample-, variant- and genotype-level quality control (QC) for the UKB 450k exome sequencing (ES) dataset following the approach of Karczewski <italic toggle="yes">et al</italic>.<sup><xref rid="R28" ref-type="bibr">28</xref></sup>. Broad continental genetic ancestry labels (Africans, Admixed Americans, East Asians, Europeans, South Asians) were assigned following the approach described by Lassen <italic toggle="yes">et al</italic>.<sup><xref rid="R29" ref-type="bibr">29</xref></sup>, using a random forest (RF) classifier trained on the 1000 Genomes dataset<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. We subset to individuals with European genetic ancestry, resulting in a high quality call set of 402,375 samples and 25,229,669 variants.</p></sec><sec id="S4"><title>Variant consequence annotation</title><p id="P14">We annotated ES variants using Variant Effect Predictor (VEP) v105 (corresponding to GENCODE v39)<sup><xref rid="R31" ref-type="bibr">31</xref></sup> with the Loss-Of-Function Transcript Effect Estimator (LOFTEE) v1.04_GRCh38<sup><xref rid="R32" ref-type="bibr">32</xref></sup> and dbNSFP<sup><xref rid="R33" ref-type="bibr">33</xref></sup> plugins, annotating variants with Combined Annotation Dependent Depletion (CADD) v1.6<sup><xref rid="R34" ref-type="bibr">34</xref></sup>, and Rare Exome Variant Ensemble Learner (REVEL) using dbNSFP4.3<sup><xref rid="R35" ref-type="bibr">35</xref></sup> and loss-of-function (LoF) confidence using LOFTEE. We provide code and instructions for this step in our VEP_105_LOFTEE repository<sup><xref rid="R36" ref-type="bibr">36</xref></sup>, which contains a Docker/Singularity container for reproducibility of annotations. Next, we ran SpliceAI v1.3<sup><xref rid="R37" ref-type="bibr">37</xref></sup> using the GENCODE v39 gene annotation file to ensure alignment between VEP and SpliceAI transcript annotations. For variant-specific annotations we use &#8220;canonical&#8221; transcripts. We separated variants by transcript using <monospace>bcftools +split-vep</monospace> and filtered to MANE Select<sup><xref rid="R38" ref-type="bibr">38</xref></sup> protein-coding transcripts. If the gene lacked a MANE Select transcript we selected the canonical transcript defined by GENCODE v39. Using this collection of missense, pLoF, splice metrics, and annotations of variant consequence on the canonical transcript, we determined four variant categories for gene-based testing.</p></sec><sec id="S5"><title>Variant consequence categories</title><list list-type="order" id="L2"><list-item><p id="P15">High confidence pLoF: High-confidence LoF variants, as defined by LOFTEE<sup><xref rid="R32" ref-type="bibr">32</xref></sup> (LOFTEE HC).</p></list-item><list-item><p id="P16">Damaging missense/protein-altering: At least one of:
<list list-type="alpha-lower" id="L4"><list-item><p id="P17">Variant annotated as missense/start-loss/stop-loss/in-frame indel and (REVEL&#8805;0.773 or CADD&#8805;28.1 or both).</p></list-item><list-item><p id="P18">Any variant with SpliceAI delta score (DS)&#8805;0.2 where SpliceAI DS is the maximum of the set {<monospace>DS_AG, DS_AL, DS_DG, DS_DL</monospace>} for each annotated variant (where <monospace>DS_AG</monospace>, <monospace>DS_AL</monospace>, <monospace>DS_DG</monospace> and <monospace>DS_DL</monospace> are delta score (acceptor gain), delta score (acceptor loss), delta score (donor gain), and delta score (donor loss), respectively).</p></list-item><list-item><p id="P19">Low-confidence LoF variants, as defined by LOFTEE (LOFTEE LC)</p></list-item></list></p></list-item><list-item><p id="P20">Other missense/protein-altering: Missense/start-loss/stop-loss/in-frame indel not categorized in (2).</p></list-item><list-item><p id="P21">Synonymous: Synonymous variants with SpliceAI DS&lt; 0.2 in the gene.</p></list-item></list><p id="P22">REVEL and CADD score cut-offs are chosen to reflect the supporting level for pathogenicity (PP3) from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) criteria<sup><xref rid="R39" ref-type="bibr">39</xref></sup>.</p></sec><sec id="S6"><title>Phenotype curation</title><sec id="S7"><title>Continuous phenotypes</title><p id="P23">We selected phenotypes among those with &#8220;Standard polygenic risk scores (PRS)&#8221; scores available in UKB<sup><xref rid="R25" ref-type="bibr">25</xref></sup>. Standing height (UKB field ID: 50) and LDL-C (UKB field ID: 30780), the two phenotypes analyzed by a previous study of phenotype misalignment<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, were chosen to benchmark our approach.</p><p id="P24">The five other continuous traits (body mass index (BMI) [UKB field ID: 21001], estimated bone mineral density (BMD) [UKB field ID: 78], intraocular pressure (IOP) [UKB field IDs: 5262, 5254], glycated haemoglobin (HbA1c) [UKB field ID: 30750], and age at menopause (AAM) [UKB field ID: 3581]) were prioritized for inclusion based on sample size in UKB, heritability, how closely the trait available in UKB matched the trait used to create the PGS, and whether there was prior evidence of monogenic disorders or genes with strong effect contributing to trait variability (<xref rid="T3" ref-type="table">Table 2</xref>). IOP was calculated as the mean between left (UKB field ID: 5262) and right (UKB field ID: 5254) corneal-compensated measurements. We chose the corneal-compensated measurement method instead of the Goldman-correlated measurement method because it has been reported to be a better indicator for glaucomatous eyes<sup><xref rid="R40" ref-type="bibr">40</xref></sup>. For AAM, we excluded individuals who responded &#8220;Do not know&#8221; or &#8220;Prefer not to answer&#8221;.</p></sec><sec id="S8"><title>Dichotomous phenotypes</title><p id="P25">We included three dichotomous disease-status phenotypes: type 2 diabetes (T2D) (International Classification of Diseases, 10th revision (ICD-10) code: E11), coronary artery disease (CAD) (ICD-10 code: I25.1), and osteoporosis (OP) (ICD-10 codes: M80, M81). Case status was defined by ICD-10 diagnoses (UKB field ID: 41270). For each disease, individuals with the disease ICD-10 code(s) were defined as cases, while everyone lacking the disease ICD-10 code, but for whom UKB field ID 41270 was defined, were assigned control status.</p></sec><sec id="S9"><title>Polygenic scores</title><p id="P26">We used PGS determined by genomics PLC<sup><xref rid="R25" ref-type="bibr">25</xref></sup> and provided through the UKB (data field IDs in <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>) for our analyses. We chose to use the &#8220;Standard PRS&#8221; (UKB category 301) scores instead of the &#8220;Enhanced PRS&#8221; (UKB category 302) because the Standard PRS category of scores are trained solely using non-UKB data<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, making them less prone to overfitting to UKB, and as a result, due to their availability for more than three times as many UKB samples compared to the Enhanced PRS.</p></sec></sec><sec id="S10"><title>Monogenic and rare disorder gene curation</title><sec id="S11"><title>Canonical monogenic gene curation</title><p id="P27">We defined &#8220;canonical&#8221; monogenic genes as genes which are well-known for causing the most common monogenic disorders associated with the phenotype being studied, based on previous studies.</p><p id="P28">For standing height and LDL-C we selected the monogenic gene set provided in a study of misaligned individuals in a UKB subset<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, for both consistency and to check for recapitulation of associations (<xref rid="T3" ref-type="table">Table 2</xref>). For BMI, we selected the first five monogenic obesity genes discovered<sup><xref rid="R41" ref-type="bibr">41</xref></sup>: <italic toggle="yes">MC4R</italic>, <italic toggle="yes">PCSK1</italic>, <italic toggle="yes">LEP</italic>, <italic toggle="yes">POMC</italic>, <italic toggle="yes">LEPR</italic>. For bone mineral density we chose the two genes (<italic toggle="yes">COL1A1</italic>, <italic toggle="yes">COL1A2</italic>) where LoF variation is the most common cause of monogenic OP<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. For intraocular pressure we chose <italic toggle="yes">MYOC</italic>, in which mutations are the most common single-gene cause of primary open-angle glaucoma via increased intraocular pressure<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. For glycated hemoglobin we chose the genes commonly responsible for maturity-onset diabetes of the young (MODY), the most common monogenic form of diabetes<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. Within the subtypes of MODY, <italic toggle="yes">GCK</italic>-MODY (MODY2) and <italic toggle="yes">HNF1A</italic>-MODY (MODY3), caused by genetic defects in <italic toggle="yes">GCK</italic> and <italic toggle="yes">HNF1A</italic>, respectively, are the two most common subtypes, accounting for around 80% of MODY cases in the UK<sup><xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R46" ref-type="bibr">46</xref></sup>. Patients in both subtypes can present with hyperglycemia<sup><xref rid="R44" ref-type="bibr">44</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup>, which can be indicated by higher than normal HbA1c levels<sup><xref rid="R48" ref-type="bibr">48</xref></sup>. For AAM there are no common monogenic disorders. As a proxy, we selected <italic toggle="yes">CHEK2</italic>, the gene with highest strength of association in the burden test for pLoF variants for AAM in Genebass<sup><xref rid="R28" ref-type="bibr">28</xref></sup> (pLoF burden <italic toggle="yes">P</italic>=3.75 &#215; 10<sup>&#8722;32</sup>). Early menopause can be caused by primary ovarian insufficiency (POI), a partly monogenic disorder<sup><xref rid="R49" ref-type="bibr">49</xref></sup>. However, there are more than 100 putative monogenic POI genes and in UKB most POI cases are not caused by monogenic mechanisms<sup><xref rid="R49" ref-type="bibr">49</xref></sup>. For T2D we selected the four MODY genes responsible for the most common subtypes of MODY in the UK: <italic toggle="yes">HNF1A</italic>, <italic toggle="yes">GCK</italic>, <italic toggle="yes">HNF4A</italic>, <italic toggle="yes">HNF1B</italic><sup><xref rid="R45" ref-type="bibr">45</xref></sup>. For CAD we selected the same familial hypercholesterolaemia (FH) genes (<italic toggle="yes">PCSK9</italic>, <italic toggle="yes">APOB</italic>, <italic toggle="yes">LDLR</italic>) used for LDL-C, because these monogenic risk genes have been shown to interact with CAD polygenic risk to modulate overall disease risk<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. Finally, for OP we selected the same osteogenesis imperfecta (i.e. monogenic OP) genes used for BMD (<italic toggle="yes">COL1A1</italic>, <italic toggle="yes">COL1A2</italic>).</p></sec><sec id="S12"><title>Rare disorder gene curation</title><p id="P29">To broaden the scan for enrichment to more genes and objectively define gene sets causing rare disorders, we used the evidence-based, expertly-curated and frequently reviewed Genomics England (GEL) PanelApp resource<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup>.</p><p id="P30">When selecting rare disorder gene sets within the GEL PanelApp, we selected disorders that cause extreme, early-onset or monogenic forms of the phenotypes in our analysis. We only included genes rated as &#8220;Green&#8221; (diagnostic-grade, conservatively defined) in the GEL PanelApp and excluded genes where the mode of pathogenicity was &#8220;Other&#8221; or started with &#8220;Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype&#8221;. This resulted in our final list of diagnostic-grade genes for each selected GEL rare disorder, such that LoF variants in each gene were expected to cause the disorder.</p></sec></sec><sec id="S13"><title>Misaligned phenotype classification</title><sec id="S14"><title>Continuous traits</title><p id="P31">To determine individuals whose observed continuous phenotypes are aligned or misaligned with their genetically predicted phenotype, we followed Hawkes <italic toggle="yes">et al</italic>.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. Briefly, covariates are residualized from the observed phenotype. Mahalanobis distance is calculated for each individual in the bivariate distribution formed by the residualized observed phenotype and the genetically predicted phenotype, and converted to <italic toggle="yes">P</italic>-values<sup><xref rid="R51" ref-type="bibr">51</xref></sup>. Residualized observed phenotypes are then regressed against genetically predicted phenotypes and residuals are calculated for each individual. We then classify an individual as misaligned or aligned if they satisfied the following conditionsHawkes <italic toggle="yes">et al</italic>.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>:</p><sec id="S15"><title>Misaligned individuals</title><list list-type="bullet" id="L6"><list-item><p id="P32">Mahalanobis <italic toggle="yes">P</italic>-value &lt; 0.001, and</p></list-item><list-item><p id="P33">Absolute residual between residualized observed and expected phenotypes &gt; 2</p></list-item></list></sec><sec id="S16"><title>Aligned individuals</title><list list-type="bullet" id="L8"><list-item><p id="P34">Absolute residual between residualized observed and expected phenotypes &lt; 1</p></list-item></list><p id="P35">In the first residualization step, the covariates were <italic toggle="yes">sex</italic>, <italic toggle="yes">age</italic>, <italic toggle="yes">age</italic><sup>2</sup>, <italic toggle="yes">sex</italic>&#215;<italic toggle="yes">age</italic>, <italic toggle="yes">sex</italic>&#215;<italic toggle="yes">age</italic><sup>2</sup>, the first 21 principal components (PCs) (calculated on UKB genotype array data<sup><xref rid="R52" ref-type="bibr">52</xref></sup> and provided by UKB), and UKB assessment center. Unlike Hawkes <italic toggle="yes">et al</italic>.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>, we did not account for statins when adjusting LDL-C for covariates. This simplifying omission is conservative, in that it is more likely to result in false negatives than false positives, as we expect cholesterol-lowering medication to attenuate the misalignment effects of deleterious variants associated with hypercholesterolemia.</p></sec></sec><sec id="S17"><title>Case-control dichotomous traits</title><p id="P36">To contrast individuals with aligned versus misaligned disease status we set percentile thresholds on covariate-residualized PRS distributions (<xref rid="SD2" ref-type="supplementary-material">Figure S7</xref>). Percentile thresholds were chosen to compare the top versus bottom halves (threshold: 50%), quartiles (thresholds: 25%, 75%), and deciles (thresholds: 10%, 90%). This followed the approach of Lu <italic toggle="yes">et al</italic>.<sup><xref rid="R11" ref-type="bibr">11</xref></sup>, who compared the top and bottom halves of the PRS distribution using point estimates for pathogenic variant prevalence. We included more extreme thresholds (quartiles, deciles) to assess whether enrichment increased in the extremes of the distribution.</p></sec><sec id="S18"><title>Filtering to unrelated individuals</title><p id="P37">We excluded individuals with a high degree of relatedness (third degree or closer) when defining our aligned and misaligned individuals. Using relatedness estimates (<italic toggle="yes">G</italic>) from a genetic relatedness matrix (GRM) created by Scalable and Accurate Implementation of GEneralized mixed model (SAIGE)<sup><xref rid="R53" ref-type="bibr">53</xref></sup> from genotype array data, we filtered to a maximal unrelated set of individuals. We created a greedy algorithm which iterated through a list of individuals (sorted by the number of relatives, with fewest relatives first) with at least one relative (<italic toggle="yes">G</italic> &gt; 2<sup>&#8722;3.5</sup>; corresponding to relatives third degree or closer), adding their relatives to the list of individuals for removal. Individuals who had already been added to the list for removal were skipped if encountered later in the iteration. We performed this relatedness filter on each phenotype separately, pre-filtering to individuals with non-missing phenotype and covariate data before applying the relatedness filter, in order to maximize sample size for each phenotype.</p></sec></sec><sec id="S19"><title>Enrichment testing of carrier status and misaligned status</title><sec id="S20"><title>Exact tests on contingency tables</title><p id="P38">To test whether individuals misaligned with genetic expectation are enriched for a binary variable (e.g. carrier status &#8211; whether or not an individual carries one or more damaging variants in a gene), we used Fisher&#8217;s exact tests<sup><xref rid="R54" ref-type="bibr">54</xref></sup>, applied to 2 &#215; 2 contingency tables.</p><table-wrap position="anchor" id="T1" orientation="portrait"><table frame="void" rules="all"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Non-carrier</th><th align="center" valign="middle" rowspan="1" colspan="1">Carrier</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Aligned</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">a</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">b</italic>
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Upper/lower misaligned</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">c</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">d</italic>
</td></tr></tbody></table></table-wrap></sec><sec id="S21"><title>Calculating empirical <italic toggle="yes">P</italic>-values with simulated polygenic scores</title><p id="P39">Spurious misaligned enrichment is possible in our continuous trait misalignment testing framework, whether due to a phenotype effect that is stronger than the misaligned effect, a PGS which explains limited phenotype variability, or a combination of both (<xref rid="SD2" ref-type="supplementary-material">Figure S2</xref>). To avoid these possibilities, we calculate an empirical <italic toggle="yes">P</italic>-value.</p><p id="P40">To establish empirical null distributions for enrichment test statistics, we tested the misalignment enrichment method using simulated PGS. The simulated PGS were generated independently of phenotypes, which means the expected phenotypic variance explained is zero. The PGS were simulated from a multivariate standard normal distribution, with zero covariance between individuals.</p><p id="P41">For each real (using non-simulated PGS) enrichment test in which there were carriers of deleterious variants, we estimated the empirical null by generating replicates of enrichment test statistics based on simulated PGS rather than real PGS (<xref rid="SD2" ref-type="supplementary-material">Figure S2</xref>). This involved running the misalignment classification procedure using simulated PGS instead of the real PGS, and then testing for enrichment of deleterious variants in the misaligned individuals. The empirical <italic toggle="yes">P</italic>-value was calculated by the following equation:
<disp-formula id="FD1"><mml:math id="M1" display="block"><mml:mrow><mml:msub><mml:mi>P</mml:mi><mml:mrow><mml:mtext>emp</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>r</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
where <italic toggle="yes">n</italic> is the number of test statistic replicates drawn from the null and <italic toggle="yes">r</italic> is the number of those replicate test statistics which are greater than or equal to the observed test statistic<sup><xref rid="R55" ref-type="bibr">55</xref>,<xref rid="R56" ref-type="bibr">56</xref></sup>. We used &#8722;log<sub>10</sub>(one-sided Fisher&#8217;s exact test <italic toggle="yes">P</italic>) as our test statistic when calculating the empirical <italic toggle="yes">P</italic>-value. We did not exclude replicates where misaligned individuals lacked the variants we were testing; instead, we assigned a Fisher&#8217;s exact test <italic toggle="yes">P</italic> = 1.</p><p id="P42">We simulated 10,000 replicates for all FDR-adjusted significant trait-gene-consequence combinations from enrichment tests of canonical and GEL genes. We simulated 1,000 replicates to test significant genes resulting from the exome-wide scan. We used a reduced number of replicates for the exome-wide scan genes due to the high computational and financial cost when running replicates on the DNAnexus Research Analysis Platform (RAP).</p></sec><sec id="S22"><title>Hypergeometric test for probability of observing no carriers</title><p id="P43">When testing misaligned individuals for enrichment of rare (MAF &lt; 0.1%) pLoF variants in monogenic disorder genes, there were many instances where, due to the rarity of being misaligned compounded with the rarity of carrying rare pLoF variants, there were no misaligned individuals carrying rare pLoF variants. To quantify the high likelihood of observing no overlap in misaligned status and pLoF carrier status, we used the hypergeometric distribution to calculate the probability of observing no carriers (<italic toggle="yes">k</italic>=0) in a sample of <italic toggle="yes">n</italic> individuals (mis-aligned individuals) from a larger group of <italic toggle="yes">N</italic> individuals (aligned and misaligned individuals) with <italic toggle="yes">K</italic> carriers.</p><disp-formula id="FD2"><mml:math id="M2" display="block"><mml:mrow><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>;</mml:mo><mml:mi>n</mml:mi><mml:mo>,</mml:mo><mml:mi>N</mml:mi><mml:mo>,</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>K</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>N</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>K</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>n</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>n</mml:mi></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:mi>N</mml:mi><mml:mo>&#8722;</mml:mo><mml:mi>K</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>n</mml:mi></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi>N</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>n</mml:mi></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></sec><sec id="S23"><title>Burden testing on phenotype misalignment</title><p id="P44">We used REGENIE version 4.1<sup><xref rid="R57" ref-type="bibr">57</xref></sup> to perform gene-level rare variant (MAF &lt; 0.1%) burden testing of phenotype misalignment for continuous (for exome-wide scan) and dichotomous traits (for canonical and GEL gene enrichment tests and exome-wide scan), using individuals with European genetic ancestry in the ES 450k tranche of UKB.</p><p id="P45">In REGENIE step 1, we fit the null model using UKB genotype array data QCed with PLINK<sup><xref rid="R58" ref-type="bibr">58</xref></sup> (Filtering flags: <monospace>--maf 0.01 --mac 100 --geno 0.1 --mind 0.1</monospace>). We included <italic toggle="yes">sequencing tranche</italic>, the tranche in which an individual was exome sequenced, as the only covariate. All other standard covariates (e.g. <italic toggle="yes">age</italic>, <italic toggle="yes">sex</italic>, PCs) had already been regressed out of the observed phenotype (continuous traits) or out of the PRS (dichotomous traits).</p><p id="P46">After fitting the null model in step 1, we carried out gene-level burden testing in REGENIE step 2 for pLoF (continuous and dichotomous traits) and damaging missense (continuous traits only) variants with MAF &lt; 0.1% using the UKB ES 450k tranche data.</p><p id="P47">To test for an association between rare deleterious variation and misaligned status in continuous traits, we treated misaligned status as a dichotomous phenotype (using the <monospace>--bt</monospace> flag in REGENIE). We tested high misaligned vs. aligned and low misaligned vs. aligned separately. When testing misalignment in disease status, we did not apply inverse rank-normal transformation (IRNT) to residualized PRS within REGENIE because the PRS were already normalized.</p><p id="P48">To compare the statistical power in testing misaligned individuals for gene enrichment to traditional approaches, we ran gene burden tests on the original continuous and dichotomous phenotypes used as input to the misaligned phenotype classification framework. We applied IRNT within REGENIE to all continuous phenotypes using the <monospace>--apply-rint</monospace> flag, and used the <monospace>--bt</monospace> flag for dichotomous traits.</p></sec><sec id="S24"><title>Conditioning on common imputed variants when testing misaligned disease status</title><p id="P49">When testing rare variant burden effects on common-variant PRS for misaligned disease status, there is a possibility that PRS could correlate with rare variants at a given gene due to linkage disequilibrium (LD). This would lead to spurious burden associations. To conditionally orthogonalize the PRS from rare variant burden, we conditioned on common (&gt; 0.1%) imputed v3 variants located in or within a 1 Mb radius of gene(s) tested (LD in Europeans tends not to extend beyond 1 Mb<sup><xref rid="R30" ref-type="bibr">30</xref></sup>), with gene start and stop locations in GRCh37 coordinates to match the imputed v3 variants. We used PLINK to QC these variants, following similar filtering thresholds use to select variants which generated the PRS<sup><xref rid="R25" ref-type="bibr">25</xref></sup> (PLINK filtering flags: <monospace>--maf 0.001 --hwe 1e-10</monospace>, variants with INFO score &lt; 0.8 excluded). We conditioned on these QCed variants in REGENIE step 2 by passing a gene-specific (or grouped-gene) PLINK pgen file with the flag <monospace>--condition-file</monospace>. In our exome-wide scan for misaligned disease status, we performed this conditioning on FDR-significant genes to check robustness of our results.</p></sec></sec><sec id="S25"><title>Defining significant associations</title><p id="P50">For each stage of enrichment tests, we applied the Benjamini-Hochberg (BH) procedure to all associations, adjusting for FDR &#8804; 5%. Statistically significant associations were defined as having FDR-adjusted <italic toggle="yes">P</italic> &lt; 0.05. As our gene sets (canonical genes, GEL gene panels, exome-wide scan) overlapped, we excluded previously tested genes from consideration when calculating FDR-adjusted <italic toggle="yes">P</italic>-values. After FDR correction, we filtered results on gene-level allele counts, to avoid spurious associations in genes with low allele counts. For continuous trait misaligned status testing, only genes with minor allele count (MAC)&#8805; 5 in the misaligned group being tested were retained. For dichotomous trait misaligned disease status testing, only genes with alternate allele count (AAC)&#8805; 10 were retained.</p></sec></sec><sec id="S26"><title>Results</title><sec id="S27"><title>Identifying individuals with misaligned continuous phenotypes</title><p id="P51">Individuals were classified as deviating from their genetically expected phenotype if their observed phenotype, adjusted for covariates, is a significant outlier in the bivariate distribution of phenotype and PGS and if the covariate-residualised observed phenotype does not align with a linear model for observed phenotype and PGS (<xref rid="S2" ref-type="sec">Methods</xref>). We applied this method to seven continuous traits in UKB, with the percentage of misaligned individuals ranging from 0.07% (HbA1c) to 0.12% (AAM)(<xref rid="F1" ref-type="fig">Figure 1</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S1</xref>; <xref rid="SD2" ref-type="supplementary-material">Figure S1</xref>).</p></sec><sec id="S28"><title>Individuals with misaligned continuous phenotypes are enriched for predicted loss-of-function variants in monogenic disorder genes</title><p id="P52">Following categorization into aligned and misaligned individuals, misaligned individuals can be further split into those whose covariate-residualized observed phenotype is higher-than-expected (&#8220;high misaligned&#8221;) and lower-than-expected (&#8220;low misaligned&#8221;), relative to their PGS. In our enrichment tests, we tested for enrichment in one of the misaligned groups (either high or low misaligned) against the aligned group, with the aligned group acting as a control group (<xref rid="S2" ref-type="sec">Methods</xref>; <xref rid="F1" ref-type="fig">Figure 1</xref>).</p><p id="P53">We are interested in finding genes which significantly contribute to phenotype misalignment. Due to the sparsity of rare deleterious variant carrier status and misaligned status, and their overlap, we wish to control the possibility of spurious associations. Misaligned individuals also tend to have extreme covariate-residualized phenotypes. As the canonical and GEL genes we test are known to associate with the traits tested, we expect carrier status to cluster among individuals with extreme covariate-residualized phenotypes (high or low extremes depending on the effect direction of the gene). Thus, we want to be sure that the misaligned associations we observe are distinct from extreme phenotype associations. Related to this, if a PGS explains limited phenotypic variability, the slope of the phenotype-PGS regression will be close to zero. This would result in phenotype-PGS residuals which directly correspond to the covariate-residualized phenotype. Thus, the misalignment enrichment test would reduce to a test on the phenotype, a similar issue to the overlap between misaligned individuals and individuals with extreme covariate-residualized phenotypes.</p><p id="P54">To increase confidence that any continuous trait misalignment enrichment is distinct from extreme phenotype association and the PGS explains a sufficient amount of phenotypic variability, we calculated an empirical <italic toggle="yes">P</italic>-value for each putatively significant enrichment result by comparing the observed test statistic (one-sided Fisher&#8217;s exact test <italic toggle="yes">P</italic>-value) against an empirical null distribution of test statistics (<xref rid="S2" ref-type="sec">Methods</xref>; <xref rid="SD2" ref-type="supplementary-material">Figure S2</xref>).</p><p id="P55">We tested misaligned individuals for enrichment of rare (MAF &lt; 0.1%) pLoF variants (see <xref rid="S2" ref-type="sec">Methods</xref> for variant consequence definitions) in genes known to cause monogenic disorders relevant to the misaligned phenotype (<xref rid="S2" ref-type="sec">Methods</xref>).</p></sec><sec id="S29"><title>Height and LDL-C</title><p id="P56">Grouping variants across the monogenic stature disorder genes (<xref rid="T3" ref-type="table">Table 2</xref>), we observed significant enrichment (FDR-adjusted one-sided Fisher&#8217;s exact test <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) of pLoF variants in individuals with shorter-than-expected stature (odds ratio (OR) [90% confidence interval (CI)] = 85.7 [49.4&#8211;149], <italic toggle="yes">P</italic><sub>adj</sub> = 1.13 &#215; 10<sup>&#8722;15</sup>) (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). We also tested single genes and observed significant enrichment in individuals with shorter-than-expected stature for <italic toggle="yes">ACAN</italic> (OR [90% CI] = 367 [188&#8211;717], <italic toggle="yes">P</italic><sub>adj</sub> = 3.02 &#215; 10<sup>&#8722;17</sup>), <italic toggle="yes">IGF1</italic> (OR [90% CI] = 1280 [125&#8211;13200], <italic toggle="yes">P</italic><sub>adj</sub> = 4.08&#215;10<sup>&#8722;3</sup>), and <italic toggle="yes">SHOX</italic> (OR [90% CI] = 183 [31.4&#8211;1070], <italic toggle="yes">P</italic><sub>adj</sub> = 0.0148) (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>).</p><p id="P57">When testing a set of FH-related genes (<xref rid="T3" ref-type="table">Table 2</xref>), we found that individuals with high or low LDL-C were enriched for pLoF variants in genes where loss of function is known to cause high (<italic toggle="yes">LDLR</italic> OR [90% CI] = 213 [96.8&#8211;468], <italic toggle="yes">P</italic><sub>adj</sub> = 3.31 &#215; 10<sup>&#8722;10</sup>) or low LDL-C (<italic toggle="yes">APOB</italic> OR [90% CI] = 153 [106&#8211;220], <italic toggle="yes">P</italic><sub>adj</sub> = 9.45 &#215; 10<sup>&#8722;45</sup>; <italic toggle="yes">PCSK9</italic> OR [90% CI] = 45.0 [24.6&#8211;82.4], <italic toggle="yes">P</italic><sub>adj</sub> = 1.29 &#215; 10<sup>&#8722;10</sup>), respectively (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). Individuals with lower than genetically expected LDL-C were also enriched for carrying the combined burden of <italic toggle="yes">PCSK9</italic> and <italic toggle="yes">APOB</italic> pLoF variants (OR [90% CI] = 105 [75.9&#8211;146], <italic toggle="yes">P</italic><sub>adj</sub> = 5.86 &#215; 10<sup>&#8722;51</sup>) (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>).</p></sec><sec id="S30"><title>Additional continuous phenotypes</title><p id="P58">For other continuous phenotypes, no misaligned individuals carry pLoF variants in genes causing monogenic disorders (<xref rid="SD2" ref-type="supplementary-material">Figure S3</xref>; <xref rid="T3" ref-type="table">Table 2</xref>), likely due to the extremely low frequency of these variants in a population cohort such as UKB. In each trait-gene pair there was a relatively high probability (minimum of hypergeometric test <italic toggle="yes">P</italic>(carriers = 0) = 0.83; <xref rid="S2" ref-type="sec">Methods</xref>) of observing zero pLoF carriers in the set of misaligned individuals, given the number of carriers in the group of misaligned and aligned individuals tested.</p><p id="P59">Missense variants which are deleterious but not predicted to result in loss of function (&#8220;damaging missense&#8221; variants; <xref rid="S2" ref-type="sec">Methods</xref>) are by definition expected to have less of an effect on gene product than pLoFs. Assuming a causal link between gene product and phenotype, this implies that damaging missense variants are also expected to have attenuated effect sizes on the phenotype compared to pLoF variants. Although effect size is generally attenuated for damaging missense variants, they tend to occur in higher frequencies. For example, the aggregated pLoF allele count across genes tested for enrichment was 3,114; for damaging missense alleles the count was 17,984, almost six-fold higher. We hypothesized that testing damaging missense variants instead might boost power in enrichment testing by increasing the number of carriers of putatively damaging variation, albeit at smaller effect size, among misaligned individuals.</p></sec><sec id="S31"><title>Individuals with misaligned continuous phenotypes are enriched for predicted damaging missense variants in monogenic disorder genes</title><p id="P60">We tested for enrichment of damaging missense variants in misaligned individuals with the same methods as for pLoF variants, for the same set of continuous traits and corresponding monogenic disorder genes.</p><p id="P61">We observed a significant enrichment (Fisher&#8217;s exact test FDR-adjusted <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) of damaging missense variants for four of the nine genes/gene sets where misaligned individuals were enriched for pLoF burden (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). Individuals with higher than genetically expected height were enriched for damaging missense variants in <italic toggle="yes">FBN1</italic> (OR [90% CI]= 3.79 [1.80&#8211;7.97], <italic toggle="yes">P</italic><sub>adj</sub> = 0.0254). For LDL-C, high misaligned individuals were enriched for damaging missense variants in <italic toggle="yes">LDLR</italic> (OR [90% CI] = 55.7 [35.5&#8211;87.4], <italic toggle="yes">P</italic><sub>adj</sub> = 3.09 &#215; 10<sup>&#8722;21</sup>), while low misaligned individuals were enriched for damaging missense variants in <italic toggle="yes">APOB</italic> (OR [90% CI] = 13.0 [6.87&#8211;24.6], <italic toggle="yes">P</italic><sub>adj</sub> = 5.64 &#215; 10<sup>&#8722;6</sup>) and grouped <italic toggle="yes">APOB</italic> and <italic toggle="yes">PCSK9</italic> variants (OR [90% CI]= 12.0 [6.59&#8211;21.8], <italic toggle="yes">P</italic><sub>adj</sub> = 2.18 &#215; 10<sup>&#8722;8</sup>).</p><p id="P62">As expected, given that we are testing monogenic genes where damaging missense variants are predicted (<xref rid="S2" ref-type="sec">Methods</xref>) to have a less deleterious effect than pLoF variants, the enrichment of damaging missense variants consistently had lower OR point estimates than pLoF variants (4/4 single- and grouped-gene tests with FDR &#8804; 5% significant pLoF and damaging missense enrichment, <xref rid="F2" ref-type="fig">Figure 2</xref>).</p></sec><sec id="S32"><title>Individuals whose continuous phenotype is misaligned with genetic expectation are enriched for predicted damaging variants in genes related to rare disorders</title><p id="P63">Having demonstrated that misaligned individuals are enriched for both pLoF and damaging missense variation in monogenic genes for continuous traits, we expanded the set of genes analyzed to include genes which cause rare disorders related to the traits analyzed. To do this, we extracted genes from the expertly-reviewed GEL PanelApp gene sets<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup> for rare diseases relevant to the phenotypes included in our analysis (<xref rid="S2" ref-type="sec">Methods</xref>). We restricted analysis to genes which qualified for the highest-confidence category (&#8220;Green&#8221;), designated to be of &#8220;diagnostic-grade&#8221;<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R50" ref-type="bibr">50</xref></sup>.</p><p id="P64">We tested all continuous traits for enrichment of pLoF and damaging missense variants in GEL rare disease genes in misaligned individuals. We used the same enrichment testing framework as described above for the canonical monogenic genes. We excluded 7.69% (38/494) of single- and grouped-gene masks because they had already been included in the enrichment testing of canonical monogenic disorder genes. We performed the BH procedure<sup><xref rid="R59" ref-type="bibr">59</xref></sup> to control FDR at 5% across all pLoF and damaging missense enrichment tests for continuous traits.</p><p id="P65">There were four single- and grouped-gene masks across three traits (height, LDL-C, BMD) for which misaligned individuals were significantly enriched (Fisher&#8217;s exact test FDR-adjusted <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) for pLoF or damaging missense variants (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD2" ref-type="supplementary-material">Figure S4</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>).</p><p id="P66">Individuals with lower than genetically expected BMD were enriched for pLoF variants in <italic toggle="yes">COPB2</italic> (OR [90% CI]=1150 [112&#8211;11900], <italic toggle="yes">P</italic><sub>adj</sub>=0.0325) and <italic toggle="yes">GORAB</italic> (OR [90% CI]=155 [44.5&#8211;539], <italic toggle="yes">P</italic><sub>adj</sub> = 3.17 &#215; 10<sup>&#8722;3</sup>), genes selected from the osteogenesis imperfecta gene panel in GEL PanelApp (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>). Both of these genes also demonstrated significant empirical <italic toggle="yes">P</italic>-values (<italic toggle="yes">P</italic><sub>emp &lt;</sub> 0.05) (<xref rid="SD2" ref-type="supplementary-material">Figure S5</xref>).</p><p id="P67">Individuals with higher than genetically expected LDL-C and individuals with lower-than-expected height were also enriched for deleterious variant burden in grouped GEL PanelApp genes. However, these significant enrichments were driven largely by the canonical monogenic genes previously tested, with attenuated odds ratios compared to the results of the grouped canonical monogenic genes (<xref rid="F2" ref-type="fig">Figure 2</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S2</xref>).</p></sec><sec id="S33"><title>Individuals whose disease status is misaligned with genetically expected risk are enriched for predicted loss-of-function variants in monogenic genes</title><p id="P68">We examined misaligned disease status relative to PRS in three common complex diseases: T2D, CAD, and OP. These diseases have been included in previous UKB studies involving PRS and penetrance of pathogenic variants<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R13" ref-type="bibr">13</xref></sup>. We tested the hypotheses that (1) disease cases with low PRS are enriched for pathogenic rare pLoF variants and (2) disease controls with high PRS are enriched for protective rare pLoF variants.</p><p id="P69">For each hypothesis, we took a two-step approach. First, within a given disease status group (cases or controls), we used linear regression to test the association of PRS with (pathogenic or protective) pLoF carrier status. Carrier status is a binary variable, defined as whether or not an individual carries at least one pLoF in the gene(s) tested. Second, similar to earlier work in a smaller subset of UKB<sup><xref rid="R11" ref-type="bibr">11</xref></sup>, we defined low and high PRS percentile groups and tested enrichment of pLoFs between the groups.</p><p id="P70">To validate our approach, we first applied it to binarized versions of height and LDL-C, continuous traits for which we have already observed an enrichment of rare deleterious variants in individuals whose phenotypes deviate from genetic expectation. Among simulated dichotomized traits with case prevalences of 5% and 10% (similar to the common diseases we aim to study), we replicated all but one (8/9) FDR-significant single- and grouped-gene pLoF associations for misaligned height and LDL-C at nominal significance (one-sided <italic toggle="yes">t</italic>-test <italic toggle="yes">P</italic> &lt; 0.05) (<xref rid="SD2" ref-type="supplementary-material">Figure S6</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S3</xref>). This demonstrated proof-of-concept that our pLoF enrichment testing approach for dichotomous case-control traits could recapitulate similar pLoF enrichment in misaligned individuals observed for continuous traits.</p></sec><sec id="S34"><title>Disease cases with low polygenic risk are enriched for rare pathogenic predicted loss-of-function variants in monogenic disorder genes</title><p id="P71">Among T2D, CAD, and OP cases we tested for association of rare (MAF &lt; 0.1%) pathogenic pLoF burden with lower PRS. We also tested for association of pLoF burden in low-PRS cases versus high-PRS cases. As with the enrichment testing of misaligned continuous traits, we used a curated set of canonical monogenic disorder genes (<xref rid="T4" ref-type="table">Table 3</xref>; <xref rid="S2" ref-type="sec">Methods</xref>). Our burden tests were conditioned on common imputed variants in or within 1 Mb of each gene being tested (<xref rid="S2" ref-type="sec">Methods</xref>). We performed the BH<sup><xref rid="R59" ref-type="bibr">59</xref></sup> procedure to control FDR at 5% separately for the regression association tests and Fisher&#8217;s exact tests.</p><p id="P72">In T2D cases, pLoF burden was significantly associated (FDR-adjusted one-sided burden <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) with lower PRS for burden in <italic toggle="yes">HNF1A</italic> (<italic toggle="yes">&#946;</italic> [90% CI] = &#8722;0.788 [&#8722;1.09, &#8722;0.484], <italic toggle="yes">P</italic> = 1.03 &#215; 10<sup>&#8722;5</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 1.44 &#215; 10<sup>&#8722;4</sup>) and <italic toggle="yes">HNF4A</italic> (<italic toggle="yes">&#946;</italic> [90% CI] = &#8722;1.88 [&#8722;3.08, &#8722;0.685], <italic toggle="yes">P</italic> = 4.83 &#215; 10<sup>&#8722;3</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 0.0338), with nominally significant (one-sided <italic toggle="yes">P</italic> &lt; 0.05) burden associations in <italic toggle="yes">GCK</italic> and grouped genes (<xref rid="F3" ref-type="fig">Figure 3a</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>).</p><p id="P73">When testing pLoF enrichment in low vs. high-PRS T2D cases for these single- or grouped-gene masks, we observed a monotonic trend in increasing OR point estimates when comparing ever more extreme PRS quantiles (<xref rid="F3" ref-type="fig">Figure 3b</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S5</xref>). This suggests that enrichment of pLoFs increases as we compare increasingly misaligned-with-genetic-expectation individuals (low-PRS cases) to increasingly aligned-with-genetic-expectation individuals (high-PRS cases).</p></sec><sec id="S35"><title>Disease controls with high polygenic risk are enriched for rare protective predicted loss-of-function variants in monogenic disorder genes</title><p id="P74">We tested for enrichment of rare pLoF variants in <italic toggle="yes">APOB</italic>, <italic toggle="yes">PCSK9</italic>, and <italic toggle="yes">ANGPTL3</italic> for CAD controls, and <italic toggle="yes">SLC30A8</italic> for T2D controls; these are genes where LoF is expected to be protective for the corresponding disease (<xref rid="T4" ref-type="table">Table 3</xref>; <xref rid="F4" ref-type="fig">Figure 4a</xref>). Among CAD controls, we observed nominally significant (one-sided burden <italic toggle="yes">P</italic> &lt; 0.05) association of pLoF burden in <italic toggle="yes">ANGPTL3</italic> with increased CAD PRS (<italic toggle="yes">&#946;</italic> [90% CI] = 0.0449 [4.22&#215;10<sup>&#8722;3</sup>, 0.0856], <italic toggle="yes">P</italic> = 0.0347, <italic toggle="yes">P</italic><sub>adj</sub> = 0.108). Comparing relative enrichment of pLoF carriers in disease controls with high versus low PRS, odds ratio point estimates did not demonstrate the same monotonicity observed for pathogenic pLoFs in disease cases (<xref rid="F4" ref-type="fig">Figure 4b</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S5</xref>).</p></sec><sec id="S36"><title>Limited evidence for enrichment of predicted loss-of-function variants in GEL genes for disease cases with misaligned disease status</title><p id="P75">We extended our analysis in dichotomous trait misalignment from canonical genes to GEL gene panels. There were no GEL genes where pLoF burden associated significantly (FDR-adjusted one-sided burden <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) with lower PRS in cases (<xref rid="SD1" ref-type="supplementary-material">Table S4</xref>). There were three genes with nominal associations: <italic toggle="yes">BMP1</italic> for OP (<italic toggle="yes">&#946;</italic> [90% CI] = &#8722;0.618 [&#8722;1.18, &#8722;0.0573], <italic toggle="yes">P</italic> = 0.0349), <italic toggle="yes">LMNA</italic> for T2D (<italic toggle="yes">&#946;</italic> [90% CI] = &#8722;0.567 [&#8722;1.12, &#8722;0.0117], <italic toggle="yes">P</italic> = 0.0465), and <italic toggle="yes">LIPA</italic> for CAD (<italic toggle="yes">&#946;</italic> [90% CI] = &#8722;0.479 [&#8722;0.956, &#8722;2.70 &#215; 10<sup>&#8722;3</sup>], <italic toggle="yes">P</italic> = 0.0490).</p></sec><sec id="S37"><title>Exome-wide scan for genes associated with misaligned status in continuous traits</title><p id="P76">Hypothesizing that there may be genes associated with misaligned status that were not included in the canonical or GEL gene sets, we scanned all genes for deleterious missense variation associated with misaligned status. Genes where deleterious missense variation causes individuals to have lower than genetically expected disease risk, or lower-than-expected liability phenotype, would be ideal targets for therapeutic deactivation. Conversely, a gene where missense variation is pathogenic could be therapeutically targeted for increased expression, assuming druggability of the gene.</p><p id="P77">For misaligned status of each continuous trait, we performed gene burden testing of rare (MAF &lt; 0.1%) pLoF and damaging missense variants with REGENIE<sup><xref rid="R57" ref-type="bibr">57</xref></sup>, testing separately for protective and pathogenic effects on phenotype misalignment (<xref rid="S2" ref-type="sec">Methods</xref>). Protective effects were defined as those which are trait decreasing, except for BMD and AAM where protective effects are trait increasing. Pathogenic effects are defined as trait-increasing, except for BMD and AAM where they are trait-decreasing. For continuous phenotypes, these definitions are oriented by the diseases of interest for which the continuous phenotypes act as liability phenotypes. The exception was height, where protective effects were defined to be trait decreasing and pathogenic effects trait increasing. These directions were arbitrarily chosen, as there exist both disorders of short and tall stature. When testing misaligned status for protective or pathogenic effects, we always test for enrichment in the misaligned group corresponding to the effect on the original trait (lower-than-expected misaligned when effect is negative, higher-than-expected misaligned when effect is positive).</p><p id="P78">Burden test <italic toggle="yes">P</italic>-values were controlled using the BH procedure<sup><xref rid="R59" ref-type="bibr">59</xref></sup> for FDR&#8804; 5% across all phenotypes and all genes, separately for protective and pathogenic misalignment tests, with previously tested canonical monogenic disorder and GEL genes excluded. Following FDR control, genes were filtered to those with MAC&#8805; 5 in the misaligned group being tested, to limit spurious associations. An empirical null <italic toggle="yes">P</italic>-value was calculated for each significant gene enrichment result (<xref rid="SD2" ref-type="supplementary-material">Figure S9</xref>; <xref rid="S2" ref-type="sec">Methods</xref>).</p></sec><sec id="S38"><title>Protective effect enrichment tests</title><p id="P79">In our exome-wide burden tests for &#8220;protective&#8221; misaligned status (lower-than-expected misalignment, except for BMD and AAM), 37 genes across six traits harboured significant enrichment (FDR-adjusted one-sided burden <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) of pLoF or damaging missense variants (<xref rid="F5" ref-type="fig">Figure 5a</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>).</p><p id="P80">For lower-than-expected BMI misalignment (9 significant genes), damaging missense associations with plausible biological mechanisms included two genes with links to fat metabolism: <italic toggle="yes">ACSL6</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 1.99 &#215; 10<sup>&#8722;4</sup>, <italic toggle="yes">P</italic><sub>adj</sub>=0.0182, <italic toggle="yes">P</italic><sub>emp</sub> = 0.106; <xref rid="F5" ref-type="fig">Figure 5a</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>), involved in lipid synthesis, such that knockdown in rat skeletal muscle results in decreased lipid accumulation<sup><xref rid="R68" ref-type="bibr">68</xref></sup>, and <italic toggle="yes">FAT1</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 1.12 &#215; 10<sup>&#8722;4</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 0.0116, <italic toggle="yes">P</italic><sub>emp</sub> = 0.0260), involved in fatty acid conversion<sup><xref rid="R69" ref-type="bibr">69</xref></sup>. The gene with the strongest association, <italic toggle="yes">NPL</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 1.06 &#215; 10<sup>&#8722;9</sup>, <italic toggle="yes">P</italic><sub>adj</sub>=6.94 &#215; 10<sup>&#8722;7</sup>, <italic toggle="yes">P</italic><sub>emp</sub> = 9.99 &#215; 10<sup>&#8722;4</sup>), has prior experimental evidence supporting a plausible link with decreased BMI. Deficiency of NPL has been shown to result in loss of skeletal muscle in humans, zebrafish, and mice<sup><xref rid="R70" ref-type="bibr">70</xref></sup>. This loss of muscle mass could lead to lower-than-expected BMI.</p><p id="P81">For lower-than-expected HbA1c misalignment (8 significant genes), we replicated several known HbA1c associations, including <italic toggle="yes">PIEZO1</italic><sup><xref rid="R71" ref-type="bibr">71</xref></sup>, and two genes (<italic toggle="yes">SLC4A1</italic> and <italic toggle="yes">ANK1</italic>) linked with hereditary spherocytosis<sup><xref rid="R72" ref-type="bibr">72</xref></sup>, a disorder which can lead to low HbA1c measurements<sup><xref rid="R73" ref-type="bibr">73</xref></sup>.</p><p id="P82">Individuals with higher-than-expected AAM were enriched for damaging missense variants in <italic toggle="yes">KANK1</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 1.55&#215;10<sup>&#8722;10</sup>, <italic toggle="yes">P</italic><sub>adj</sub>=1.27&#215;10<sup>&#8722;7</sup>, <italic toggle="yes">P</italic><sub>emp</sub> = 3.00&#215;10<sup>&#8722;3</sup>; <xref rid="F5" ref-type="fig">Figure 5a</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). <italic toggle="yes">KANK1</italic> is a uterine fibroid risk gene<sup><xref rid="R74" ref-type="bibr">74</xref></sup>, much like <italic toggle="yes">CHEK2</italic>, a tumor suppressor gene<sup><xref rid="R75" ref-type="bibr">75</xref></sup> where LoF has previously been shown to be associated with increased AAM<sup><xref rid="R76" ref-type="bibr">76</xref></sup>. Uterine fibroids become less common after menopause<sup><xref rid="R77" ref-type="bibr">77</xref></sup>, so if damaging variation in a gene was protective for primary ovarian insufficiency, increasing AAM, it might extend the window of time for uterine fibroids to appear, increasing the odds of developing uterine fibroids. When assessing the original trait, association of damaging missense burden in <italic toggle="yes">KANK1</italic> with AAM was null in our study (two-sided burden <italic toggle="yes">P</italic> = 0.964) and Genebass<sup><xref rid="R28" ref-type="bibr">28</xref></sup> (missense|low-confidence loss-of-function (LC) burden <italic toggle="yes">P</italic> = 0.879).</p></sec><sec id="S39"><title>Pathogenic effect enrichment tests</title><p id="P83">In our exome-wide burden tests for &#8220;pathogenic&#8221; misaligned status (higher-than-expected misalignment, except for BMD and AAM), 37 genes across five traits harbored significant enrichment (FDR-adjusted one-sided burden <italic toggle="yes">P</italic><sub>adj</sub> &#8804; 0.05) of pLoF or damaging missense variants (<xref rid="F5" ref-type="fig">Figure 5b</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>).</p><p id="P84">For taller-than-expected height, significant enrichment was observed for both pLoF (4 genes) and damaging missense variants (26 genes). Several of the significant genes are known to cause autosomal recessive genetic syndromes which can result in short stature, including <italic toggle="yes">SPINK5</italic> (Netherton syndrome<sup><xref rid="R78" ref-type="bibr">78</xref></sup>), <italic toggle="yes">PLOD2</italic> (Bruck syndrome<sup><xref rid="R79" ref-type="bibr">79</xref></sup>), and <italic toggle="yes">GALNS</italic> (Morquio syndrome/mucopolysaccharidosis type IV<sup><xref rid="R80" ref-type="bibr">80</xref></sup>). These are counter to the direction of effect expected for taller-than-expected height misalignment, however none of the taller-than-expected height outliers were homozygous or compound heterozygous carriers of ClinVar<sup><xref rid="R81" ref-type="bibr">81</xref></sup> pathogenic variants from the variant category (pLoF or damaging missense) being tested (<xref rid="SD2" ref-type="supplementary-material">Figure S8</xref>). This suggests that these carriers are unlikely to have these syndromes, resolving this paradox.</p><p id="P85">For higher-than expected LDL-C (2 significant genes), one gene with a biologically plausible mechanism was <italic toggle="yes">TSC2</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 2.01 &#215; 10<sup>&#8722;4</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 0.0188, <italic toggle="yes">P</italic><sub>emp</sub> = 4.00 &#215; 10<sup>&#8722;3</sup>; <xref rid="F5" ref-type="fig">Figure 5b</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). <italic toggle="yes">TSC2</italic> inhibits the protein kinase mechanistic target of rapamycin complex 1 (mTORC1)<sup><xref rid="R82" ref-type="bibr">82</xref></sup>; when mTORC1 is left uninhibited, it can promote <italic toggle="yes">de novo</italic> lipogenesis<sup><xref rid="R83" ref-type="bibr">83</xref></sup>. The other significant gene, <italic toggle="yes">ANK2</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 1.09&#215;10<sup>&#8722;6</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 2.96&#215;10<sup>&#8722;4</sup>), has been strongly implicated in cardiac arrhythmias<sup><xref rid="R84" ref-type="bibr">84</xref></sup>, but no evidence in the literature suggests that cardiac arrhythmia can cause high cholesterol.</p><p id="P86">For higher-than-expected HbA1c misalignment, the only significant association was for damaging missense burden in <italic toggle="yes">PIK3C2B</italic> (burden <italic toggle="yes">P</italic><sub>misaligned</sub> = 2.93&#215;10<sup>&#8722;4</sup>, <italic toggle="yes">P</italic><sub>adj</sub> = 0.0252, <italic toggle="yes">P</italic><sub>emp</sub> = 0.218; <xref rid="F5" ref-type="fig">Figure 5b</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S6</xref>). There is a plausible pathway implicating this gene in HbA1c, as it encodes a protein involved in the PI3K/AKT/mTOR pathway, a critical regulator of insulin signalling and overall glucose homeostasis<sup><xref rid="R85" ref-type="bibr">85</xref>,<xref rid="R86" ref-type="bibr">86</xref></sup>.</p><p id="P87">For the remaining traits, there were significant pathogenic damaging missense burden associations for higher-than-expected BMI (<italic toggle="yes">KLHL17</italic>) and lower-than-expected BMD (<italic toggle="yes">OTOG</italic>, <italic toggle="yes">ABCC2</italic>, <italic toggle="yes">MTMR2</italic>). However, these genes did not have strong evidence from existing literature to support their biological plausibility.</p></sec></sec><sec id="S40"><title>Discussion</title><p id="P88">In this study, we tested a collection of continuous and dichotomous traits for enrichment of rare deleterious variants in individuals whose observed phenotype deviates from common-variant genetic expectation. We began with a narrow focus, testing a small curated set of genes canonically implicated in each trait, before expanding to testing larger gene panels from GEL for rare disorders related to the traits. Finally, we broaden our scope to an exome-wide scan, searching for novel gene burden associations with phenotype misalignment.</p><p id="P89">Using an existing method of misaligned phenotype classification in continuous traits, we replicated many of the pLoF enrichment results previously observed<sup><xref rid="R26" ref-type="bibr">26</xref></sup> for misaligned height and LDL-C. We also found that individuals with lower than genetically expected LDL-C and higher than genetically expected stature were enriched for rare damaging missense variants in <italic toggle="yes">APOB</italic> and <italic toggle="yes">FBN1</italic>, respectively. This suggests that phenotype misalignment may be influenced by variants expected to have more moderate effects on gene function. Another novel observation was that in BMD, a trait not investigated by previous studies of misaligned phenotypes, misaligned individuals were enriched for rare pLoF variants in <italic toggle="yes">COPB2</italic> and <italic toggle="yes">GORAB</italic>, genes linked with a monogenic form of OP. These results further validate the use of misalignment classification for prioritizing individuals when screening of rare genetic disorders related to height, LDL-C, and BMD.</p><p id="P90">Testing for pLoF enrichment in individuals misaligned with disease status, we found that T2D disease cases carrying pathogenic rare pLoFs in certain MODY genes tended to have significantly lower PRS. We also observed that CAD disease controls carrying nominally-significant protective rare pLoFs in <italic toggle="yes">ANGPTL3</italic> tended to have higher PRS. As with the continuous traits, these results support the use of PRS when prioritizing individuals for rare disorder screening. These results also provide strong evidence of a liability threshold model where disease status is determined by a balance of pathogenic and protective effects from common and rare variants (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p><p id="P91">Moving from validation to discovery, we tested exome-wide for genes associated with protective or pathogenic misaligned continuous phenotype status and identified several genes with plausible biological pathways for their role in causing high or low misaligned phenotypes, including genes associated with lower-than-expected BMI (<italic toggle="yes">ACSL6</italic>, <italic toggle="yes">FAT1</italic>, <italic toggle="yes">NPL</italic>) and higher-than-expected LDL-C (<italic toggle="yes">TSC2</italic>) and AAM (<italic toggle="yes">KANK1</italic>). This demonstrated that misalignment classification of continuous traits could improve power in gene discovery, especially for noisy self-reported phenotypes, such as AAM<sup><xref rid="R87" ref-type="bibr">87</xref></sup>. We also performed an exome-wide scan for genes associated with misaligned disease status (<xref rid="SD2" ref-type="supplementary-material">Supplementary Note 1</xref>), but this was less fruitful, yielding a single association in <italic toggle="yes">HLA-DRB5</italic> for CAD-protective pLoF burden. This could be because there are not many genes with effect sizes large enough to counteract common variant effects and cause misaligned disease status.</p><p id="P92">There were some limitations in this study. First, testing for enrichment of rare damaging variants among misaligned individuals has inherently limited statistical power due to the few or absent variant carriers among misaligned individuals. For example, when testing continuous traits, there were zero variant carriers in misaligned individuals for more than half (32/58) of the canonical monogenic gene enrichment tests and 78.7% (389/494) of GEL PanelApp gene enrichment tests, across all pLoF and damaging missense enrichment tests. This made it impossible to assess relative enrichment of damaging variants in misaligned individuals versus aligned individuals in these instances. In addition to the double jeopardy in statistical power when testing for enrichment of rare variants in a rare group of individuals, there are also expected to be fewer pathogenic variants in UKB because, on average, UKB participants are healthier than the general population<sup><xref rid="R88" ref-type="bibr">88</xref></sup>. Second, we used variant consequence categories based on computational prediction (see <xref rid="S2" ref-type="sec">Methods</xref>) rather than strictly clinical evidence. Using computational prediction may lead to some miscategorized variants, but enabled us to scale the enrichment tests to many more variants than would be feasible through manual curation of single variants informed by clinical case studies. Third, throughout this paper we use PGS/PRS generated by a single study<sup><xref rid="R25" ref-type="bibr">25</xref></sup>, provided by UKB. We chose these scores because they were rigorously defined, readily available, and generated independently from our work. Evaluating the performance of our misalignment testing approach across PGS generated by other methods could further generalize our findings and determine what aspects of a PGS make it particularly suited to misalignment testing. Finally, this study was performed solely in individuals classified as having European genetic ancestry (<xref rid="S2" ref-type="sec">Methods</xref>). Identifying misaligned individuals in non-European populations is difficult, as these populations are generally less represented in genome-wide association study (GWAS) with sufficient sample size to generate informative PGS. However, as increasingly diverse large biobanks are created, such as the All of Us (AoU) dataset<sup><xref rid="R89" ref-type="bibr">89</xref></sup>, misalignment classification will become feasible for more ancestry groups.</p><p id="P93">There are several areas of opportunity to build off of this work. We could investigate whether non-genetic factors, such as socioeconomic status, diet, or medications, could explain phenotype misalignment. Correcting for these non-genetic factors could also improve power for detecting rare genetic effects on misalignment. Replication of results in an independent cohort, such as the AoU dataset<sup><xref rid="R89" ref-type="bibr">89</xref></sup>, would further increase confidence in results. Stratifying analysis by sex or another categorical variable and investigating category-specific enrichment, could provide more granularity to the results. However, stratification would increase the multiple testing burden and also decrease the sample size in enrichment tests. Hypothesizing that singletons observed in UKB could be harboring large-effect variants such as <italic toggle="yes">de novo</italic> variants, misaligned individuals could be tested for enrichment of singleton burden. We performed this analysis and found moderate evidence pointing to deleterious singleton burden associating with shorter-than-expected stature (<xref rid="SD2" ref-type="supplementary-material">Supplementary Note 2</xref>). Singleton burden analysis could be refined by calling <italic toggle="yes">de novo</italic> variants and testing their burden directly, however this was beyond the scope of this project. Unlike the gene-level tests used throughout our work, performing a variant-level exome-wide scan for association could highlight the specific variants driving gene-level associations. However, this higher-resolution approach may only be practical for rare but not ultra rare variants, as statistical power to detect very rare variant associations (e.g. MAC &#8804; 10) is attenuated compared to associations in more common variants with the same effect size<sup><xref rid="R90" ref-type="bibr">90</xref></sup>. Lastly, when performing exome-wide scans for novel protective genetic effects associated with PRS in disease controls, we only tested pLoF burden. This was because we expected pLoFs to have a much stronger effect than other missense variants, with a strong effect presumably necessary to cause disease status misalignment. However, as observed when testing gene burden associated with misaligned status in continuous traits, there may be value in expanding to damaging missense variants.</p><p id="P94">We demonstrated that for a range of heritable continuous traits and complex diseases, misaligned individuals are enriched for rare damaging variants. This work highlights the value in considering both common and rare genetic components of trait variability, as it may prioritize certain individuals for rare disease diagnosis and could be leveraged to find new pathogenic or protective associations.</p></sec><sec id="S41"><title>Resource availability</title><sec id="S42"><title>Lead contact</title><p id="P95">Requests for further information and resources should be directed to and will be fulfilled by the lead contact, NAB (<email>nikolasbaya@gmail.com</email>).</p></sec><sec sec-type="data-availability" id="S43"><title>Data and code availability</title><p id="P96">Summary statistics for all analyses not already available in the <xref rid="SD2" ref-type="supplementary-material">supplementary materials</xref> are available upon reasonable request to the authors. All code used in this study will be made available through GitHub upon publication.</p></sec></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="media-1.xlsx" id="d67e2182" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><label>1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="NIHPP2025.12.30.25343229V1-supplement-1.pdf" id="d67e2185" position="anchor" orientation="portrait"/></supplementary-material></sec></body><back><ack id="S44"><title>Acknowledgments</title><p id="P97">This research was conducted using the UK Biobank resource under application number 11867. We thank UK Biobank participants for their contribution.</p><sec id="S45"><title>Funding acknowledgments</title><p id="P98">NAB is supported by the Pembroke College Oxford-Bendich Graduate Scholarship, the Clarendon Fund, and Wellcome Trust Grant Number 224890/Z/21/Z. SSV is supported by the Rhodes Scholarships, Clarendon Fund, and the Medical Sciences Doctoral Training Centre at the University of Oxford. FHL is supported by the Wellcome Trust (award 224894/Z/21/Z) and the Medical Sciences Doctoral Training Centre at the University of Oxford. CML is supported by the Li Ka Shing Foundation, NIHR Oxford Biomedical Research Centre, Oxford, NIH (1P50HD104224-01), Gates Foundation (INV-024200). This research was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z, and Wellcome Trust Residual award (221782/Z/20/Z) with additional support from the NIHR Oxford BRC. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. HC is supported by Wellcome (318918/Z/24/Z) and NIH (1P50HD104224-01).</p></sec></ack><fn-group><fn id="FN3"><p id="P99">Transparent methods</p><p id="P100">This study used data from the UK Biobank. The North West Multi-centre Research Ethics Committee (MREC) gave approval to UK Biobank as a Research Tissue Bank (RTB) approval. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.</p></fn><fn fn-type="COI-statement" id="FN4"><p id="P101">Declaration of interests</p><p id="P102">SSV is currently employed by Illumina but while she conducted the research described in this manuscript was only affiliated with the University of Oxford. CML is currently a part-time employee of the Ellison Institute of Technology and Population Health Partners (PHP), is chief science officer of Aneira Health, owns equity in PHP and its subsidiaries, and has a partner who works at Vertex. The other authors declare no competing interests.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Falconer</surname><given-names>D. S.</given-names></name><article-title>The inheritance of liability to certain diseases, estimated from the incidence among relatives</article-title>. en. <source>Ann. Hum. Genet.</source><volume>29</volume>, <fpage>51</fpage>&#8211;<lpage>76</lpage> (<issue>1</issue><month>Aug</month>. <year>1965</year>).</mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zuk</surname><given-names>O.</given-names></name>, <name name-style="western"><surname>Hechter</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Sunyaev</surname><given-names>S. R.</given-names></name>, <etal/><article-title>The mystery of missing heritability: Genetic interactions create phantom heritability</article-title>. en. <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>109</volume>, <fpage>1193</fpage>&#8211;<lpage>1198</lpage> (<issue>4</issue><month>Jan</month>. <day>24</day>, <year>2012</year>).<pub-id pub-id-type="pmid">22223662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1119675109</pub-id><pub-id pub-id-type="pmcid">PMC3268279</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gibson</surname><given-names>G.</given-names></name><article-title>Rare and common variants: twenty arguments</article-title>. en. <source>Nat. Rev. Genet.</source><volume>13</volume>, <fpage>135</fpage>&#8211;<lpage>145</lpage> (<issue>2</issue><month>Jan</month>. <day>18</day>, <year>2012</year>).<pub-id pub-id-type="pmid">22251874</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrg3118</pub-id><pub-id pub-id-type="pmcid">PMC4408201</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name> &amp; <name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><article-title>Genetic prediction of complex traits with polygenic scores: a statistical review</article-title>. en. <source>Trends Genet.</source><volume>37</volume>, <fpage>995</fpage>&#8211;<lpage>1011</lpage> (<issue>11</issue><month>Nov</month>. <year>2021</year>).<pub-id pub-id-type="pmid">34243982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tig.2021.06.004</pub-id><pub-id pub-id-type="pmcid">PMC8511058</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wray</surname><given-names>N. R.</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>M. E.</given-names></name> &amp; <name name-style="western"><surname>Visscher</surname><given-names>P. M.</given-names></name><article-title>Prediction of individual genetic risk to disease from genome-wide association studies</article-title>. en. <source>Genome Res</source><volume>17</volume>, <fpage>1520</fpage>&#8211;<lpage>1528</lpage> (<issue>10</issue><month>Oct</month>. <year>2007</year>).<pub-id pub-id-type="pmid">17785532</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/gr.6665407</pub-id><pub-id pub-id-type="pmcid">PMC1987352</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khera</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Emdin</surname><given-names>C. A.</given-names></name>, <name name-style="western"><surname>Drake</surname><given-names>I.</given-names></name>, <etal/><article-title>Genetic risk, adherence to a healthy lifestyle, and coronary disease</article-title>. en. <source>N. Engl. J. Med.</source><volume>375</volume>, <fpage>2349</fpage>&#8211;<lpage>2358</lpage> (<issue>24</issue><month>Dec</month>. <day>15</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27959714</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1605086</pub-id><pub-id pub-id-type="pmcid">PMC5338864</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maas</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Barrdahl</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>A. D.</given-names></name>, <etal/><article-title>Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the United States</article-title>. en. <source>JAMA Oncol</source>. <volume>2</volume>, <fpage>1295</fpage>&#8211;<lpage>1302</lpage> (<issue>10</issue><month>Oct</month>. <day>1</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27228256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamaoncol.2016.1025</pub-id><pub-id pub-id-type="pmcid">PMC5719876</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Natarajan</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Young</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Stitziel</surname><given-names>N. O.</given-names></name>, <etal/><article-title>Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting</article-title>. en. <source>Circulation</source><volume>135</volume>, <fpage>2091</fpage>&#8211;<lpage>2101</lpage> (<issue>22</issue><month>May</month><day>30</day>, <year>2017</year>).<pub-id pub-id-type="pmid">28223407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.116.024436</pub-id><pub-id pub-id-type="pmcid">PMC5484076</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Torkamani</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Wineinger</surname><given-names>N. E.</given-names></name> &amp; <name name-style="western"><surname>Topol</surname><given-names>E. J.</given-names></name><article-title>The personal and clinical utility of polygenic risk scores</article-title>. en. <source>Nat. Rev. Genet.</source><volume>19</volume>, <fpage>581</fpage>&#8211;<lpage>590</lpage> (<issue>9</issue><month>Sept</month>. <year>2018</year>).<pub-id pub-id-type="pmid">29789686</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-018-0018-x</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jurgens</surname><given-names>S. J.</given-names></name>, <name name-style="western"><surname>Pirruccello</surname><given-names>J. P.</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>S. H.</given-names></name>, <etal/><article-title>Adjusting for common variant polygenic scores improves yield in rare variant association analyses</article-title>. <source>Nature genetics</source><volume>55</volume> (<issue>4</issue><month>Apr</month>. <year>2023</year>).</mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lu</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name>, <etal/><article-title>Individuals with common diseases but with a low polygenic risk score could be prioritized for rare variant screening</article-title>. en. <source>Genet. Med.</source><volume>23</volume>, <fpage>508</fpage>&#8211;<lpage>515</lpage> (<issue>3</issue><month>Mar</month>. <year>2021</year>).<pub-id pub-id-type="pmid">33110269</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41436-020-01007-7</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>Q. Q.</given-names></name>, <name name-style="western"><surname>Wigdor</surname><given-names>E. M.</given-names></name>, <name name-style="western"><surname>Malawsky</surname><given-names>D. S.</given-names></name>, <etal/><article-title>Examining the role of common variants in rare neurodevelopmental conditions</article-title>. en. <source>Nature</source><volume>636</volume>, <fpage>404</fpage>&#8211;<lpage>411</lpage> (<issue>8042</issue><month>Dec</month>. <year>2024</year>).<pub-id pub-id-type="pmid">39567701</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-024-08217-y</pub-id><pub-id pub-id-type="pmcid">PMC11634775</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fahed</surname><given-names>A. C.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Homburger</surname><given-names>J. R.</given-names></name>, <etal/><article-title>Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions</article-title>. en. <source>Nature Communications</source><volume>11</volume>, <fpage>1</fpage>&#8211;<lpage>9</lpage> (<issue>1</issue><month>Aug</month>. <day>20</day>, <year>2020</year>).</mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kuchenbaecker</surname><given-names>K. B.</given-names></name>, <name name-style="western"><surname>McGuffog</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Barrowdale</surname><given-names>D.</given-names></name>, <etal/><article-title>Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers</article-title>. en. <source>J Natl Cancer Inst</source><volume>109</volume>, <fpage>djw302</fpage> (<issue>7</issue><month>Mar</month>. <day>9</day>, <year>2017</year>).<pub-id pub-id-type="pmid">28376175</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jnci/djw302</pub-id><pub-id pub-id-type="pmcid">PMC5408990</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mars</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Wid&#233;n</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Kerminen</surname><given-names>S.</given-names></name>, <etal/><article-title>The role of polygenic risk and susceptibility genes in breast cancer over the course of life</article-title>. en. <source>Nature Communications</source><volume>11</volume>, <fpage>1</fpage>&#8211;<lpage>9</lpage> (<issue>1</issue><month>Dec</month>. <day>14</day>, <year>2020</year>).</mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><article-title>Identification of Genetic Factors that Modify Clinical Onset of Huntington&#8217;s Disease</article-title>. <source>Cell</source><volume>162</volume>, <fpage>516</fpage>&#8211;<lpage>526</lpage> (<issue>3</issue><month>July</month><day>30</day>, <year>2015</year>).<pub-id pub-id-type="pmid">26232222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.07.003</pub-id><pub-id pub-id-type="pmcid">PMC4524551</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Moss</surname><given-names>D. J. H.</given-names></name>, <name name-style="western"><surname>Pardi&#241;as</surname><given-names>A. F.</given-names></name>, <name name-style="western"><surname>Langbehn</surname><given-names>D.</given-names></name>, <etal/><article-title>Identification of genetic variants associated with Huntington&#8217;s disease progression: a genome-wide association study</article-title>. en. <source>Lancet Neurol.</source><volume>16</volume>, <fpage>701</fpage>&#8211;<lpage>711</lpage> (<issue>9</issue><month>Sept</month>. <year>2017</year>).<pub-id pub-id-type="pmid">28642124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1474-4422(17)30161-8</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Craig</surname><given-names>J. E.</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Qassim</surname><given-names>A.</given-names></name>, <etal/><article-title>Multitrait analysis of glaucoma identifies new risk loci and enables polygenic prediction of disease susceptibility and progression</article-title>. en. <source>Nature Genetics</source><volume>52</volume>, <fpage>160</fpage>&#8211;<lpage>166</lpage> (<issue>2</issue><month>Jan</month>. <day>20</day>, <year>2020</year>).<pub-id pub-id-type="pmid">31959993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0556-y</pub-id><pub-id pub-id-type="pmcid">PMC8056672</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zebardast</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Sekimitsu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name>, <etal/><article-title>Characteristics of p.Gln368Ter myocilin variant and influence of polygenic risk on glaucoma penetrance in the UK Biobank</article-title>. en. <source>Ophthalmology</source><volume>128</volume>, <fpage>1300</fpage>&#8211;<lpage>1311</lpage> (<issue>9</issue><month>Sept</month>. <year>2021</year>).<pub-id pub-id-type="pmid">33713785</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2021.03.007</pub-id><pub-id pub-id-type="pmcid">PMC9134646</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Oetjens</surname><given-names>M. T.</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>M. A.</given-names></name>, <name name-style="western"><surname>Sturm</surname><given-names>A. C.</given-names></name>, <etal/><article-title>Quantifying the polygenic contribution to variable expressivity in eleven rare genetic disorders</article-title>. en. <source>Nature Communications</source><volume>10</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage> (<issue>1</issue><month>Oct</month>. <day>25</day>, <year>2019</year>).</mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kingdom</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Beaumont</surname><given-names>R. N.</given-names></name>, <name name-style="western"><surname>Wood</surname><given-names>A. R.</given-names></name>, <etal/><article-title>Genetic modifiers of rare variants in monogenic developmental disorder loci</article-title>. en. <source>Nature Genetics</source><volume>56</volume>, <fpage>861</fpage>&#8211;<lpage>868</lpage> (<issue>5</issue><month>Apr</month>. <day>18</day>, <year>2024</year>).<pub-id pub-id-type="pmid">38637616</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-024-01710-0</pub-id><pub-id pub-id-type="pmcid">PMC11096126</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Niemi</surname><given-names>M. E. K.</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>H. C.</given-names></name>, <name name-style="western"><surname>Rice</surname><given-names>D. L.</given-names></name>, <etal/><article-title>Common genetic variants contribute to risk of rare severe neurodevelopmental disorders</article-title>. en. <source>Nature</source><volume>562</volume>, <fpage>268</fpage>&#8211;<lpage>271</lpage> (<issue>7726</issue><month>Sept</month>. <day>26</day>, <year>2018</year>).<pub-id pub-id-type="pmid">30258228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0566-4</pub-id><pub-id pub-id-type="pmcid">PMC6726472</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Nestor</surname><given-names>J. G.</given-names></name>, <etal/><article-title>Polygenic risk alters the penetrance of monogenic kidney disease</article-title>. en. <source>Nature Communications</source><volume>14</volume>, <fpage>1</fpage>&#8211;<lpage>10</lpage> (<issue>1</issue><month>Dec</month>. <day>14</day>, <year>2023</year>).</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tansey</surname><given-names>K. E.</given-names></name>, <name name-style="western"><surname>Rees</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Linden</surname><given-names>D. E.</given-names></name>, <etal/><article-title>Common alleles contribute to schizophrenia in CNV carriers</article-title>. en. <source>Molecular Psychiatry</source><volume>21</volume>, <fpage>1085</fpage>&#8211;<lpage>1089</lpage> (<issue>8</issue><month>Sept</month>. <day>22</day>, <year>2015</year>).<pub-id pub-id-type="pmid">26390827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mp.2015.143</pub-id><pub-id pub-id-type="pmcid">PMC4960448</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Thompson</surname><given-names>D. J.</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Selzam</surname><given-names>S.</given-names></name>, <etal/><article-title>A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS) Release</article-title>. <source>PLOS ONE</source><volume>19</volume>, <fpage>e0307270</fpage> (<issue>9</issue><month>Sept</month>. <day>18</day>, <year>2024</year>).<pub-id pub-id-type="pmid">39292644</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0307270</pub-id><pub-id pub-id-type="pmcid">PMC11410272</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hawkes</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Yengo</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Vedantam</surname><given-names>S.</given-names></name>, <etal/><article-title>Identification and analysis of individuals who deviate from their genetically-predicted phenotype</article-title>. en. <source>PLoS Genet</source><volume>19</volume>, <fpage>e1010934</fpage> (<day>9</day><month>Sept</month>. <year>2023</year>).<pub-id pub-id-type="pmid">37733769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pgen.1010934</pub-id><pub-id pub-id-type="pmcid">PMC10564121</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Martin</surname><given-names>A. R.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Foulger</surname><given-names>R. E.</given-names></name>, <etal/><article-title>PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels</article-title>. en. <source>Nature Genetics</source><volume>51</volume>, <fpage>1560</fpage>&#8211;<lpage>1565</lpage> (<issue>11</issue><month>Nov</month>. <day>1</day>, <year>2019</year>).<pub-id pub-id-type="pmid">31676867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-019-0528-2</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Karczewski</surname><given-names>K. J.</given-names></name>, <name name-style="western"><surname>Solomonson</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chao</surname><given-names>K. R.</given-names></name>, <etal/><article-title>Systematic single-variant and gene-based association testing of thousands of phenotypes in 394,841 UK Biobank exomes</article-title>. en. <source>Cell Genom.</source><volume>2</volume>, <fpage>100168</fpage> (<issue>9</issue><month>Sept</month>. <day>14</day>, <year>2022</year>).<pub-id pub-id-type="pmid">36778668</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xgen.2022.100168</pub-id><pub-id pub-id-type="pmcid">PMC9903662</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lassen</surname><given-names>F. H.</given-names></name>, <name name-style="western"><surname>Venkatesh</surname><given-names>S. S.</given-names></name>, <name name-style="western"><surname>Baya</surname><given-names>N.</given-names></name>, <etal/><article-title>Exome-wide evidence of compound heterozygous effects across common phenotypes in the UK Biobank</article-title>. en. <source>Cell Genom.</source><volume>4</volume>, <fpage>100602</fpage> (<issue>7</issue><month>July</month><day>10</day>, <year>2024</year>).<pub-id pub-id-type="pmid">38944039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xgen.2024.100602</pub-id><pub-id pub-id-type="pmcid">PMC11293579</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><collab>1000 Genomes Project Consortium</collab>, <name name-style="western"><surname>Auton</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Brooks</surname><given-names>L. D.</given-names></name>, <etal/><article-title>A global reference for human genetic variation</article-title>. en. <source>Nature</source><volume>526</volume>, <fpage>68</fpage>&#8211;<lpage>74</lpage> (<issue>7571</issue><month>Oct</month>. <day>1</day>, <year>2015</year>).<pub-id pub-id-type="pmid">26432245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature15393</pub-id><pub-id pub-id-type="pmcid">PMC4750478</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McLaren</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Gil</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Hunt</surname><given-names>S. E.</given-names></name>, <etal/><article-title>The Ensembl Variant Effect Predictor</article-title>. en. <source>Genome Biol.</source><volume>17</volume>, <fpage>122</fpage> (<issue>1</issue><month>June</month><day>6</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27268795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13059-016-0974-4</pub-id><pub-id pub-id-type="pmcid">PMC4893825</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Karczewski</surname><given-names>K. J.</given-names></name>, <name name-style="western"><surname>Francioli</surname><given-names>L. C.</given-names></name>, <name name-style="western"><surname>Tiao</surname><given-names>G.</given-names></name>, <etal/><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title>. en. <source>Nature</source><volume>581</volume>, <fpage>434</fpage>&#8211;<lpage>443</lpage> (<issue>7809</issue><month>May</month><year>2020</year>).<pub-id pub-id-type="pmid">32461654</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2308-7</pub-id><pub-id pub-id-type="pmcid">PMC7334197</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Mou</surname><given-names>C.</given-names></name>, <etal/><article-title>dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs</article-title>. en. <source>Genome Med.</source><volume>12</volume>, <fpage>103</fpage> (<issue>1</issue><month>Dec</month>. <day>2</day>, <year>2020</year>).<pub-id pub-id-type="pmid">33261662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13073-020-00803-9</pub-id><pub-id pub-id-type="pmcid">PMC7709417</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rentzsch</surname><given-names>P.</given-names></name>, <name name-style="western"><surname>Witten</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>G. M.</given-names></name>, <etal/><article-title>CADD: predicting the deleteriousness of variants throughout the human genome</article-title>. en. <source>Nucleic Acids Res.</source><volume>47</volume>, <fpage>D886</fpage>&#8211;<lpage>D894</lpage> (<issue>D1</issue><month>Jan</month>. <day>8</day>, <year>2019</year>).<pub-id pub-id-type="pmid">30371827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gky1016</pub-id><pub-id pub-id-type="pmcid">PMC6323892</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ioannidis</surname><given-names>N. M.</given-names></name>, <name name-style="western"><surname>Rothstein</surname><given-names>J. H.</given-names></name>, <name name-style="western"><surname>Pejaver</surname><given-names>V.</given-names></name>, <etal/><article-title>REVEL: An ensemble method for predicting the pathogenicity of rare missense variants</article-title>. en. <source>Am. J. Hum. Genet.</source><volume>99</volume>, <fpage>877</fpage>&#8211;<lpage>885</lpage> (<issue>4</issue><month>Oct</month>. <day>6</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27666373</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2016.08.016</pub-id><pub-id pub-id-type="pmcid">PMC5065685</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="webpage"><source>VEP version 105 with LOFTEE v1.04 GRCh38 containers</source> en. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/BRaVa-genetics/vep105_loftee" ext-link-type="uri">https://github.com/BRaVa-genetics/vep105_loftee</ext-link> (<year>2024</year>).</mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jaganathan</surname><given-names>K.</given-names></name>, <name name-style="western"><surname>Kyriazopoulou Panagiotopoulou</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>McRae</surname><given-names>J. F.</given-names></name>, <etal/><article-title>Predicting Splicing from Primary Sequence with Deep Learning</article-title>. en. <source>Cell</source><volume>176</volume>, <fpage>535</fpage>&#8211;<lpage>548.e24</lpage> (<issue>3</issue><month>Jan</month>. <day>24</day>, <year>2019</year>).<pub-id pub-id-type="pmid">30661751</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2018.12.015</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morales</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Pujar</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Loveland</surname><given-names>J. E.</given-names></name>, <etal/><article-title>A joint NCBI and EMBL-EBI transcript set for clinical genomics and research</article-title>. en. <source>Nature</source><volume>604</volume>, <fpage>310</fpage>&#8211;<lpage>315</lpage> (<issue>7905</issue><month>Apr</month>. <year>2022</year>).<pub-id pub-id-type="pmid">35388217</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-022-04558-8</pub-id><pub-id pub-id-type="pmcid">PMC9007741</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Richards</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Aziz</surname><given-names>N.</given-names></name>, <name name-style="western"><surname>Bale</surname><given-names>S.</given-names></name>, <etal/><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title>. en. <source>Genet. Med.</source><volume>17</volume>, <fpage>405</fpage>&#8211;<lpage>424</lpage> (<day>5</day><month>May</month><year>2015</year>).<pub-id pub-id-type="pmid">25741868</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/gim.2015.30</pub-id><pub-id pub-id-type="pmcid">PMC4544753</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ehrlich</surname><given-names>J. R.</given-names></name>, <name name-style="western"><surname>Radcliffe</surname><given-names>N. M.</given-names></name> &amp; <name name-style="western"><surname>Shimmyo</surname><given-names>M.</given-names></name><article-title>Goldmann applanation tonometry compared with corneal-compensated intraocular pressure in the evaluation of primary open-angle Glaucoma</article-title>. <source>BMC ophthalmology</source><volume>12</volume> (<month>Sept</month>. <day>25</day>, <year>2012</year>).</mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Loos</surname><given-names>R. J. F.</given-names></name> &amp; <name name-style="western"><surname>Yeo</surname><given-names>G. S. H.</given-names></name><article-title>The genetics of obesity: from discovery to biology</article-title>. en. <source>Nat. Rev. Genet.</source><volume>23</volume>, <fpage>120</fpage>&#8211;<lpage>133</lpage> (<issue>2</issue><month>Feb</month>. <year>2022</year>).<pub-id pub-id-type="pmid">34556834</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41576-021-00414-z</pub-id><pub-id pub-id-type="pmcid">PMC8459824</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>M&#228;kitie</surname><given-names>R. E.</given-names></name>, <name name-style="western"><surname>Costantini</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>K&#228;mpe</surname><given-names>A.</given-names></name>, <etal/><article-title>New Insights Into Monogenic Causes of Osteoporosis</article-title>. en. <source>Front. Endocrinol.</source><volume>10</volume>, <fpage>432844</fpage> (<month>Feb</month>. <day>25</day>, <year>2019</year>).</mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kwon</surname><given-names>Y. H.</given-names></name>, <name name-style="western"><surname>Fingert</surname><given-names>J. H.</given-names></name>, <name name-style="western"><surname>Kuehn</surname><given-names>M. H.</given-names></name>, <etal/><article-title>Primary open-angle glaucoma</article-title>. en. <source>N Engl J Med</source><volume>360</volume>, <fpage>1113</fpage>&#8211;<lpage>1124</lpage> (<issue>11</issue><month>Mar</month>. <day>12</day>, <year>2009</year>).<pub-id pub-id-type="pmid">19279343</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMra0804630</pub-id><pub-id pub-id-type="pmcid">PMC3700399</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Naylor</surname><given-names>R. N.</given-names></name>, <name name-style="western"><surname>John</surname><given-names>P. M.</given-names></name>, <name name-style="western"><surname>Winn</surname><given-names>A. N.</given-names></name>, <etal/><article-title>Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications</article-title>. en. <source>Diabetes Care</source><volume>37</volume>, <fpage>202</fpage>&#8211;<lpage>209</lpage> (<issue>1</issue><year>2014</year>).<pub-id pub-id-type="pmid">24026547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc13-0410</pub-id><pub-id pub-id-type="pmcid">PMC3867988</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Frayling</surname><given-names>T. M.</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>J. C.</given-names></name>, <name name-style="western"><surname>Bulman</surname><given-names>M. P.</given-names></name>, <etal/><article-title>beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors</article-title>. <source>Diabetes</source><volume>50 Suppl 1</volume> (<month>Feb</month>. <year>2001</year>).</mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shields</surname><given-names>B. M.</given-names></name>, <name name-style="western"><surname>Hicks</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Shepherd</surname><given-names>M. H.</given-names></name>, <etal/><article-title>Maturity-onset diabetes of the young (MODY): how many cases are we missing?</article-title><source>Diabetologia</source><volume>53</volume> (<day>12</day><month>Dec</month>. <year>2010</year>).</mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steele</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Shields</surname><given-names>B. M.</given-names></name>, <name name-style="western"><surname>Shepherd</surname><given-names>M</given-names></name>, <etal/><article-title>Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene</article-title>. en. <source>Diabet Med</source><volume>27</volume>, <fpage>157</fpage>&#8211;<lpage>161</lpage> (<issue>2</issue><month>Feb</month>. <year>2010</year>).<pub-id pub-id-type="pmid">20546258</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1464-5491.2009.02913.x</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><collab>International Expert Committee</collab>. <article-title>International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes</article-title>. en. <source>Diabetes Care</source><volume>32</volume>, <fpage>1327</fpage>&#8211;<lpage>1334</lpage> (<issue>7</issue><month>July</month><year>2009</year>).<pub-id pub-id-type="pmid">19502545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc09-9033</pub-id><pub-id pub-id-type="pmcid">PMC2699715</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Shekari</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Stankovic</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Gardner</surname><given-names>E. J.</given-names></name>, <etal/><article-title>Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency</article-title>. en. <source>Nature Medicine</source><volume>29</volume>, <fpage>1692</fpage>&#8211;<lpage>1699</lpage> (<issue>7</issue><month>June</month><day>22</day>, <year>2023</year>).</mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stark</surname><given-names>Z.</given-names></name>, <name name-style="western"><surname>Foulger</surname><given-names>R. E.</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>E.</given-names></name>, <etal/><article-title>Scaling national and international improvement in virtual gene panel curation via a collaborative approach to discordance resolution</article-title>. en. <source>Am. J. Hum. Genet.</source><volume>108</volume>, <fpage>1551</fpage>&#8211;<lpage>1557</lpage> (<issue>9</issue><month>Sept</month>. <day>2</day>, <year>2021</year>).<pub-id pub-id-type="pmid">34329581</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2021.06.020</pub-id><pub-id pub-id-type="pmcid">PMC8456155</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brereton</surname><given-names>R. G.</given-names></name><article-title>The chi squared and multinormal distributions: The chi squared and multinormal distributions</article-title>. en. <source>J. Chemom.</source><volume>29</volume>, <fpage>9</fpage>&#8211;<lpage>12</lpage> (<issue>1</issue><month>Jan</month>. <year>2015</year>).</mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bycroft</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>C.</given-names></name>, <name name-style="western"><surname>Petkova</surname><given-names>D.</given-names></name>, <etal/><article-title>The UK Biobank resource with deep phenotyping and genomic data</article-title>. en. <source>Nature</source><volume>562</volume>, <fpage>203</fpage>&#8211;<lpage>209</lpage> (<issue>7726</issue><month>Oct</month>. <year>2018</year>).<pub-id pub-id-type="pmid">30305743</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-018-0579-z</pub-id><pub-id pub-id-type="pmcid">PMC6786975</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Bi</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name>, <etal/><article-title>SAIGE-GENE+ improves the efficiency and accuracy of set-based rare variant association tests</article-title>. en. <source>Nat. Genet.</source><volume>54</volume>, <fpage>1466</fpage>&#8211;<lpage>1469</lpage> (<issue>10</issue><month>Oct</month>. <year>2022</year>).<pub-id pub-id-type="pmid">36138231</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-022-01178-w</pub-id><pub-id pub-id-type="pmcid">PMC9534766</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fisher</surname><given-names>R. A.</given-names></name><article-title>The Logic of Inductive Inference. en</article-title>. <source>Journal of the Royal Statistical Society</source><volume>98</volume>, <fpage>39</fpage>&#8211;<lpage>82</lpage> (<year>1935</year>).</mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="book"><name name-style="western"><surname>Davison</surname><given-names>A. C.</given-names></name> &amp; <name name-style="western"><surname>Hinkley</surname><given-names>D. V.</given-names></name><source>Bootstrap Methods and Their Application</source> en. <fpage>606</fpage> pp. (<publisher-name>Cambridge University Press</publisher-name>, <month>Oct</month>. <volume>28</volume>, <year>1997</year>).</mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>North</surname><given-names>B. V.</given-names></name>, <name name-style="western"><surname>Curtis</surname><given-names>D</given-names></name> &amp; <name name-style="western"><surname>Sham</surname><given-names>P. C.</given-names></name><article-title>A Note on the Calculation of Empirical P Values from Monte Carlo Procedures</article-title>. <source>American Journal of Human Genetics</source><volume>71</volume>, <fpage>439</fpage> (<day>2</day><month>Aug</month>. <year>2002</year>).<pub-id pub-id-type="pmid">12111669</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/341527</pub-id><pub-id pub-id-type="pmcid">PMC379178</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mbatchou</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Barnard</surname><given-names>L.</given-names></name>, <name name-style="western"><surname>Backman</surname><given-names>J.</given-names></name>, <etal/><article-title>Computationally efficient whole-genome regression for quantitative and binary traits</article-title>. en. <source>Nat. Genet.</source><volume>53</volume>, <fpage>1097</fpage>&#8211;<lpage>1103</lpage> (<issue>7</issue><month>July</month><year>2021</year>).<pub-id pub-id-type="pmid">34017140</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41588-021-00870-7</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Purcell</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Neale</surname><given-names>B.</given-names></name>, <name name-style="western"><surname>Todd-Brown</surname><given-names>K.</given-names></name>, <etal/><article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses</article-title>. en. <source>Am. J. Hum. Genet.</source><volume>81</volume>, <fpage>559</fpage>&#8211;<lpage>575</lpage> (<issue>3</issue><month>Sept</month>. <year>2007</year>).<pub-id pub-id-type="pmid">17701901</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/519795</pub-id><pub-id pub-id-type="pmcid">PMC1950838</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Benjamini</surname><given-names>Y.</given-names></name> &amp; <name name-style="western"><surname>Hochberg</surname><given-names>Y.</given-names></name><article-title>Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing</article-title>. <source>J. R. Stat. Soc. Series B Stat. Methodol.</source><volume>57</volume>, <fpage>289</fpage>&#8211;<lpage>300</lpage> (<issue>1</issue><year>1995</year>).</mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bonnefond</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Unnikrishnan</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Doria</surname><given-names>A.</given-names></name>, <etal/><article-title>Monogenic diabetes</article-title>. en. <source>Nat. Rev. Dis. Primers</source><volume>9</volume>, <fpage>12</fpage> (<issue>1</issue><month>Mar</month>. <day>9</day>, <year>2023</year>).<pub-id pub-id-type="pmid">36894549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41572-023-00421-w</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Flannick</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Thorleifsson</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Beer</surname><given-names>N. L.</given-names></name>, <etal/><article-title>Loss-of-function mutations in SLC30A8 protect against type 2 diabetes</article-title>. en. <source>Nat. Genet.</source><volume>46</volume>, <fpage>357</fpage>&#8211;<lpage>363</lpage> (<issue>4</issue><month>Apr</month>. <year>2014</year>).<pub-id pub-id-type="pmid">24584071</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng.2915</pub-id><pub-id pub-id-type="pmcid">PMC4051628</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cohen</surname><given-names>J. C.</given-names></name>, <name name-style="western"><surname>Boerwinkle</surname><given-names>E.</given-names></name>, <name name-style="western"><surname>Mosley</surname><given-names>T. H.</given-names><suffix>Jr</suffix></name>, <etal/><article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease</article-title>. en. <source>N Engl J Med</source><volume>354</volume>, <fpage>1264</fpage>&#8211;<lpage>1272</lpage> (<issue>12</issue><month>Mar</month>. <day>23</day>, <year>2006</year>).<pub-id pub-id-type="pmid">16554528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa054013</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ference</surname><given-names>B. A.</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>J. G.</given-names></name>, <name name-style="western"><surname>Brook</surname><given-names>R. D.</given-names></name>, <etal/><article-title>Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes</article-title>. en. <source>N. Engl. J. Med.</source><volume>375</volume>, <fpage>2144</fpage>&#8211;<lpage>2153</lpage> (<issue>22</issue><month>Dec</month>. <day>1</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27959767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1604304</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Peloso</surname><given-names>G. M.</given-names></name>, <name name-style="western"><surname>Nomura</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Khera</surname><given-names>A. V.</given-names></name>, <etal/><article-title>Rare Protein-Truncating Variants in APOB, Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease</article-title>. en. <source>Circulation: Genomic and Precision Medicine</source> (<month>May</month><year>2019</year>).</mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soutar</surname><given-names>A. K.</given-names></name> &amp; <name name-style="western"><surname>Naoumova</surname><given-names>R. P.</given-names></name><article-title>Mechanisms of Disease: genetic causes of familial hypercholesterolemia</article-title>. en. <source>Nature Clinical Practice Cardiovascular Medicine</source><volume>4</volume>, <fpage>214</fpage>&#8211;<lpage>225</lpage> (<issue>4</issue><month>Apr</month>. <year>2007</year>).</mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stitziel</surname><given-names>N. O.</given-names></name>, <name name-style="western"><surname>Khera</surname><given-names>A. V.</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name>, <etal/><article-title>ANGPTL3 deficiency and protection against coronary artery disease</article-title>. en. <source>J. Am. Coll. Cardiol.</source><volume>69</volume>, <fpage>2054</fpage>&#8211;<lpage>2063</lpage> (<issue>16</issue><month>Apr</month>. <day>25</day>, <year>2017</year>).<pub-id pub-id-type="pmid">28385496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2017.02.030</pub-id><pub-id pub-id-type="pmcid">PMC5404817</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rauch</surname><given-names>F.</given-names></name> &amp; <name name-style="western"><surname>Glorieux</surname><given-names>F. H.</given-names></name><article-title>Osteogenesis imperfecta</article-title>. en. <source>Lancet</source><volume>363</volume>, <fpage>1377</fpage>&#8211;<lpage>1385</lpage> (<issue>9418</issue><month>Apr</month>. <day>24</day>, <year>2004</year>).<pub-id pub-id-type="pmid">15110498</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(04)16051-0</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Teodoro</surname><given-names>B. G.</given-names></name>, <name name-style="western"><surname>Sampaio</surname><given-names>I. H.</given-names></name>, <name name-style="western"><surname>Bomfim</surname><given-names>L. H. M.</given-names></name>, <etal/><article-title>Long-chain acyl-CoA synthetase 6 regulates lipid synthesis and mitochondrial oxidative capacity in human and rat skeletal muscle</article-title>. <source>The Journal of Physiology</source><volume>595</volume>, <fpage>677</fpage>&#8211;<lpage>693</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">27647415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1113/JP272962</pub-id><pub-id pub-id-type="pmcid">PMC5285616</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name>, <name name-style="western"><surname>Harasymowicz</surname><given-names>N. S.</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>C.-L.</given-names></name>, <etal/><article-title>Gene therapy for fat-1 prevents obesity-induced metabolic dysfunction, cellular senescence, and osteoarthritis</article-title>. <source>Proceedings of the National Academy of Sciences</source><volume>121</volume>, <fpage>e2402954121</fpage> (<year>2024</year>).</mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Da Silva</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Dort</surname><given-names>J.</given-names></name>, <name name-style="western"><surname>Orfi</surname><given-names>Z.</given-names></name>, <etal/><article-title>N-acetylneuraminate pyruvate lyase controls sialylation of muscle glycoproteins essential for muscle regeneration and function</article-title>. en. <source>Science Advances</source><volume>9</volume>, <fpage>eade6308</fpage> (<issue>26</issue><month>June</month><day>30</day>, <year>2023</year>).<pub-id pub-id-type="pmid">37390204</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciadv.ade6308</pub-id><pub-id pub-id-type="pmcid">PMC10313170</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jacobs</surname><given-names>B. M.</given-names></name>, <name name-style="western"><surname>Stow</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Hodgson</surname><given-names>S.</given-names></name>, <etal/><article-title>Genetic architecture of routinely acquired blood tests in a British South Asian cohort</article-title>. <source>Nature Communications</source><volume>15</volume>, <fpage>8929</fpage> (<year>2024</year>).</mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Eber</surname><given-names>S. W.</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Lux</surname><given-names>M. L.</given-names></name>, <etal/><article-title>Ankyrin-1 mutations are a major cause of dominant and recessive hereditary spherocytosis</article-title>. <source>Nature Genetics</source><volume>13</volume>, <fpage>214</fpage>&#8211;<lpage>218</lpage> (<year>1996</year>).<pub-id pub-id-type="pmid">8640229</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ng0696-214</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rushakoff</surname><given-names>R. J.</given-names></name>, <name name-style="western"><surname>MacMaster</surname><given-names>H. W.</given-names></name> &amp; <name name-style="western"><surname>Shah</surname><given-names>A. D.</given-names></name><article-title>Hereditary spherocytosis and other factors that alter HBA1C levels</article-title>. en. <source>AACE Clin. Case Rep.</source><volume>1</volume>, <fpage>e212</fpage>&#8211;<lpage>e213</lpage> (<issue>3</issue><year>2015</year>).</mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gallagher</surname><given-names>C. S.</given-names></name>, <name name-style="western"><surname>M&#228;kinen</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Harris</surname><given-names>H. R.</given-names></name>, <etal/><article-title>Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis</article-title>. en. <source>Nat. Commun.</source><volume>10</volume>, <fpage>4857</fpage> (<issue>1</issue><month>Oct</month>. <day>24</day>, <year>2019</year>).<pub-id pub-id-type="pmid">31649266</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-019-12536-4</pub-id><pub-id pub-id-type="pmcid">PMC6813337</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cybulski</surname><given-names>C</given-names></name>, <name name-style="western"><surname>G&#243;rski</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Huzarski</surname><given-names>T</given-names></name>, <etal/><article-title>CHEK2 is a multiorgan cancer susceptibility gene</article-title>. en. <source>Am. J. Hum. Genet.</source><volume>75</volume>, <fpage>1131</fpage>&#8211;<lpage>1135</lpage> (<issue>6</issue><month>Dec</month>. <year>2004</year>).<pub-id pub-id-type="pmid">15492928</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1086/426403</pub-id><pub-id pub-id-type="pmcid">PMC1182149</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ruth</surname><given-names>K. S.</given-names></name>, <name name-style="western"><surname>Day</surname><given-names>F. R.</given-names></name>, <name name-style="western"><surname>Hussain</surname><given-names>J.</given-names></name>, <etal/><article-title>Genetic insights into biological mechanisms governing human ovarian ageing</article-title>. en. <source>Nature</source><volume>596</volume>, <fpage>393</fpage>&#8211;<lpage>397</lpage> (<issue>7872</issue><month>Aug</month>. <year>2021</year>).<pub-id pub-id-type="pmid">34349265</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03779-7</pub-id><pub-id pub-id-type="pmcid">PMC7611832</pub-id></mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ulin</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Ali</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Chaudhry</surname><given-names>Z. T.</given-names></name>, <etal/><article-title>Uterine Fibroids in Menopause and Perimenopause</article-title>. <source>Menopause (New York, N.Y.)</source><volume>27</volume>, <fpage>238</fpage> (<issue>2</issue><month>Feb</month>. <year>2020</year>).<pub-id pub-id-type="pmid">31834160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/GME.0000000000001438</pub-id><pub-id pub-id-type="pmcid">PMC6994343</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>J. D.</given-names></name> &amp; <name name-style="western"><surname>Linden</surname><given-names>K. G.</given-names></name><article-title>Netherton syndrome: a case report and review of the literature</article-title>. <source>International Journal of Dermatology</source><volume>45</volume>, <fpage>693</fpage>&#8211;<lpage>697</lpage> (<year>2006</year>).<pub-id pub-id-type="pmid">16796630</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-4632.2005.02637.x</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Van der Slot</surname><given-names>A. J.</given-names></name>, <name name-style="western"><surname>Zuurmond</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Bardoel</surname><given-names>A. F. J.</given-names></name>, <etal/><article-title>Identification of PLOD2 as Telopeptide Lysyl Hydroxylase, an Important Enzyme in Fibrosis</article-title>. <source>The Journal of Biological Chemistry</source><volume>278</volume>, <fpage>40967</fpage>&#8211;<lpage>40972</lpage> (<year>2003</year>).<pub-id pub-id-type="pmid">12881513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M307380200</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Monta&#241;o</surname><given-names>A. M.</given-names></name>, <name name-style="western"><surname>Tomatsu</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Brusius</surname><given-names>A.</given-names></name>, <etal/><article-title>Growth charts for patients affected with Morquio A disease</article-title>. <source>American Journal of Medical Genetics</source>, <volume>Part A 146A</volume>, <fpage>1286</fpage>&#8211;<lpage>1295</lpage> (<year>2008</year>).</mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Landrum</surname><given-names>M. J.</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>J. M.</given-names></name>, <name name-style="western"><surname>Riley</surname><given-names>G. R.</given-names></name>, <etal/><article-title>ClinVar: public archive of relationships among sequence variation and human phenotype. en</article-title>. <source>Nucleic Acids Res.</source><volume>42</volume>, <fpage>D980</fpage>&#8211;<lpage>5</lpage> (Database issue <month>Jan</month>. <year>2014</year>).<pub-id pub-id-type="pmid">24234437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkt1113</pub-id><pub-id pub-id-type="pmcid">PMC3965032</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Saxton</surname><given-names>R. A.</given-names></name> &amp; <name name-style="western"><surname>Sabatini</surname><given-names>D. M.</given-names></name><article-title>mTOR Signaling in Growth, Metabolism, and Disease</article-title>. <source>Cell</source><volume>168</volume>, <fpage>960</fpage>&#8211;<lpage>976</lpage> (<year>2017</year>).<pub-id pub-id-type="pmid">28283069</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2017.02.004</pub-id><pub-id pub-id-type="pmcid">PMC5394987</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Porstmann</surname><given-names>T.</given-names></name>, <name name-style="western"><surname>Santos</surname><given-names>C. R.</given-names></name>, <name name-style="western"><surname>Griffiths</surname><given-names>B.</given-names></name>, <etal/><article-title>SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth</article-title>. <source>Cell Metabolism</source><volume>8</volume>, <fpage>224</fpage>&#8211;<lpage>236</lpage> (<year>2008</year>).<pub-id pub-id-type="pmid">18762023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cmet.2008.07.007</pub-id><pub-id pub-id-type="pmcid">PMC2593919</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Koenig</surname><given-names>S. N.</given-names></name> &amp; <name name-style="western"><surname>Mohler</surname><given-names>P. J.</given-names></name><article-title>The Evolving Role of Ankyrin-B in Cardiovascular Disease</article-title>. en. <source>Heart Rhythm</source><volume>14</volume>, <fpage>1884</fpage>&#8211;<lpage>1889</lpage> (<issue>12</issue><month>July</month><day>29</day>, <year>2017</year>).<pub-id pub-id-type="pmid">28765088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.hrthm.2017.07.032</pub-id><pub-id pub-id-type="pmcid">PMC5712256</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name>, <etal/><article-title>PI3K/AKT Pathway and Type 2 Diabetes Mellitus</article-title>. <source>Curr. Mol. Med.</source><volume>18</volume>, <fpage>51</fpage>&#8211;<lpage>63</lpage> (<issue>1</issue><year>2018</year>).</mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Maffei</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Vitiello</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Zampella</surname><given-names>A.</given-names></name>, <etal/><article-title>PI3K/AKT/mTOR Pathway and Type 2 Diabetes: A New Therapeutic Option for the Disease</article-title>. <source>Int. J. Mol. Sci.</source><volume>19</volume>, <fpage>4098</fpage> (<issue>12</issue><month>Dec</month>. <day>21</day>, <year>2018</year>).<pub-id pub-id-type="pmid">30567315</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms19124098</pub-id><pub-id pub-id-type="pmcid">PMC6321267</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Den Tonkelaar</surname><given-names>I.</given-names></name><article-title>Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project</article-title>. en. <source>Maturitas</source><volume>27</volume>, <fpage>117</fpage>&#8211;<lpage>123</lpage> (<issue>2</issue><month>June</month><year>1997</year>).<pub-id pub-id-type="pmid">9255746</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0378-5122(97)01122-5</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Fry</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Littlejohns</surname><given-names>T. J.</given-names></name>, <name name-style="western"><surname>Sudlow</surname><given-names>C.</given-names></name>, <etal/><article-title>Comparison of sociodemographic and health-related characteristics of UK Biobank participants with those of the general population</article-title>. en. <source>Am. J. Epidemiol.</source><volume>186</volume>, <fpage>1026</fpage>&#8211;<lpage>1034</lpage> (<issue>9</issue><month>Nov</month>. <day>1</day>, <year>2017</year>).<pub-id pub-id-type="pmid">28641372</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/aje/kwx246</pub-id><pub-id pub-id-type="pmcid">PMC5860371</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><collab>All of Us Research Program Genomics Investigators</collab>. <article-title>Genomic data in the All of Us Research Program</article-title>. en. <source>Nature</source><volume>627</volume>, <fpage>340</fpage>&#8211;<lpage>346</lpage> (<issue>8003</issue><month>Mar</month>. <year>2024</year>).<pub-id pub-id-type="pmid">38374255</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-023-06957-x</pub-id><pub-id pub-id-type="pmcid">PMC10937371</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>S.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <etal/><article-title>ACAT: A fast and powerful p value combination method for rare-variant analysis in sequencing studies</article-title>. en. <source>Am. J. Hum. Genet.</source><volume>104</volume>, <fpage>410</fpage>&#8211;<lpage>421</lpage> (<issue>3</issue><month>Mar</month>. <day>7</day>, <year>2019</year>).<pub-id pub-id-type="pmid">30849328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajhg.2019.01.002</pub-id><pub-id pub-id-type="pmcid">PMC6407498</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tieber</surname><given-names>V. L.</given-names></name>, <name name-style="western"><surname>Abruzzini</surname><given-names>L. F.</given-names></name>, <name name-style="western"><surname>Didier</surname><given-names>D. K.</given-names></name>, <etal/><article-title>Complete characterization and sequence of an HLA class II DR beta chain cDNA from the DR5 haplotype</article-title>. en. <source>J. Biol. Chem.</source><volume>261</volume>, <fpage>2738</fpage>&#8211;<lpage>2742</lpage> (<issue>6</issue><month>Feb</month>. <day>25</day>, <year>1986</year>).<pub-id pub-id-type="pmid">3456344</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ajoolabady</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Pratico</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name>, <etal/><article-title>Inflammation in atherosclerosis: pathophysiology and mechanisms</article-title>. en. <source>Cell Death Dis.</source><volume>15</volume>, <fpage>817</fpage> (<issue>11</issue><month>Nov</month>. <day>11</day>, <year>2024</year>).<pub-id pub-id-type="pmid">39528464</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41419-024-07166-8</pub-id><pub-id pub-id-type="pmcid">PMC11555284</pub-id></mixed-citation></ref><ref id="R93"><label>93.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Genovese</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Fromer</surname><given-names>M.</given-names></name>, <name name-style="western"><surname>Stahl</surname><given-names>E. A.</given-names></name>, <etal/><article-title>Increased burden of ultra-rare protein-altering variants among 4,877 individuals with schizophrenia</article-title>. en. <source>Nature Neuroscience</source><volume>19</volume>, <fpage>1433</fpage>&#8211;<lpage>1441</lpage> (<issue>11</issue><month>Oct</month>. <day>3</day>, <year>2016</year>).<pub-id pub-id-type="pmid">27694994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nn.4402</pub-id><pub-id pub-id-type="pmcid">PMC5104192</pub-id></mixed-citation></ref><ref id="R94"><label>94.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Backman</surname><given-names>J. D.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>A. H.</given-names></name>, <name name-style="western"><surname>Marcketta</surname><given-names>A.</given-names></name>, <etal/><article-title>Exome sequencing and analysis of 454,787 UK Biobank participants</article-title>. en. <source>Nature</source><volume>599</volume>, <fpage>628</fpage>&#8211;<lpage>634</lpage> (<issue>7886</issue><month>Oct</month>. <day>18</day>, <year>2021</year>).<pub-id pub-id-type="pmid">34662886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-04103-z</pub-id><pub-id pub-id-type="pmcid">PMC8596853</pub-id></mixed-citation></ref><ref id="R95"><label>95.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hawkes</surname><given-names>G.</given-names></name>, <name name-style="western"><surname>Beaumont</surname><given-names>R. N.</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name>, <etal/><article-title>Whole-genome sequencing in 333,100 individuals reveals rare non-coding single variant and aggregate associations with height</article-title>. en. <source>Nat. Commun.</source><volume>15</volume>, <fpage>8549</fpage> (<issue>1</issue><month>Oct</month>. <day>3</day>, <year>2024</year>).<pub-id pub-id-type="pmid">39362880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-024-52579-w</pub-id><pub-id pub-id-type="pmcid">PMC11450065</pub-id></mixed-citation></ref><ref id="R96"><label>96.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Buniello</surname><given-names>A.</given-names></name>, <name name-style="western"><surname>Suveges</surname><given-names>D.</given-names></name>, <name name-style="western"><surname>Cruz-Castillo</surname><given-names>C.</given-names></name>, <etal/><article-title>Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery</article-title>. en. <source>Nucleic Acids Res.</source><volume>53</volume>, <fpage>D1467</fpage>&#8211;<lpage>D1475</lpage> (<issue>D1</issue><month>Jan</month>. <day>6</day>, <year>2025</year>).<pub-id pub-id-type="pmid">39657122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkae1128</pub-id><pub-id pub-id-type="pmcid">PMC11701534</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1:</label><caption><title>Overview of phenotypic misalignment analysis.</title><p id="P103">We investigated seven continuous and three dichotomous traits to determine if deviation from common-variant genetic prediction is driven by rare damaging variants. <bold>Theoretical Model:</bold> For continuous traits, misaligned individuals are defined by large residuals between observed and expected phenotypes (PGS). For dichotomous traits, under the liability threshold model, misaligned individuals include cases with low PRS) and controls with high PRS, with misalignment driven by pathogenic or protective rare variants. <bold>Methodology:</bold> Enrichment in continuous traits was assessed by comparing rare variant carrier rates in high/low misaligned groups against aligned individuals. For dichotomous traits, we utilized a two-step process: regression of PRS against rare variant burden, and enrichment testing based on PRS percentiles. <bold>Variant categories tested:</bold> We computationally annotated variants and used pLoF or putatively damaging missense variants in our enrichment and burden tests. Only pLoF variants were tested for dichotomous traits. <bold>Gene sets tested:</bold> Tests were applied in stages across canonical monogenic disorder genes, GEL PanelApp gene panel genes, and an exome-wide scan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.12.30.25343229v1-f0001.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2:</label><caption><title>Enrichment of pLoF and damaging missense variants in canonical monogenic disorder and GEL gene panel genes.</title><p id="P104">Enrichment in <bold>a</bold>, low and <bold>b</bold>, high misaligned individuals for monogenic disorder genes and <bold>c</bold>, misaligned individuals for GEL gene panels. &#8220;Low misaligned&#8221; individuals are individuals with phenotypes lower than genetically expected by PGS. &#8220;High misaligned&#8221; individuals are individuals with phenotypes higher than genetically expected by PGS. Error bars indicate two-sided 90% CI for OR, such that the lower bound indicates the lower bound for a one-sided 95% CI. Only significant enrichment results (FDR&#8804; 5%) are shown. Asterisks indicate results where the empirical <italic toggle="yes">P</italic>-value is significant (<italic toggle="yes">P</italic><sub>emp &lt;</sub> 0.05). Empirical null distributions can be seen in <xref rid="SD2" ref-type="supplementary-material">Figure S5</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.12.30.25343229v1-f0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3:</label><caption><title>Pathogenic pLoFs are associated with lower PRS in disease cases.</title><p id="P105"><bold>a</bold>, Effect of pLoF variants on PRS among disease cases. Association tests were conditioned on common (MAF &gt; 0.1%) imputed variants in or within 1 Mb of each gene tested. <bold>b</bold>, Comparing pathogenic pLoF enrichment in extremes of PRS for disease cases, for genes with significant enrichment results in <bold>(a)</bold>, except for <italic toggle="yes">HNF4A</italic>, which had insufficient carriers to perform enrichment testing in extremes. Error bars indicate two-sided 90% CI for OR, such that the upper bound in <bold>(a)</bold> or lower bound in <bold>(b)</bold> indicates the upper or lower bound, respectively, for a one-sided 95% CI. pLoF, predicted loss-of-function; PRS, polygenic risk score; CAD, coronary artery disease; OP, osteoporosis; T2D, type 2 diabetes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.12.30.25343229v1-f0003.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4:</label><caption><title>Protective pLoFs are associated with higher PRS in disease controls.</title><p id="P106"><bold>a</bold>, Effect of pLoF variants on PRS among disease controls. Association tests were conditioned on common (MAF &gt; 0.1%) imputed variants in or within 1 Mb of each gene tested. <bold>b</bold>, Comparing pathogenic pLoF enrichment in extremes of PRS for disease controls, for genes with significant enrichment results in <bold>(a)</bold>. Error bars indicate two-sided 90% CI for OR, such that the lower bound indicates the lower bound for a one-sided 95% CI. pLoF, predicted loss-of-function; PRS, polygenic risk score; CAD, coronary artery disease; T2D, type 2 diabetes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.12.30.25343229v1-f0004.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5:</label><caption><title>Strength of misaligned burden association, comparing burden test on original phenotype versus burden test of misaligned status.</title><p id="P107"><bold>a</bold>, Protective misaligned effect. <bold>b</bold>, Pathogenic misaligned effect. <italic toggle="yes">P</italic><sub>misaligned</sub> is a one-sided <italic toggle="yes">P</italic>-value, with the alternate hypothesis that burden of damaging variants is higher in misaligned individuals (cases) than aligned individuals (controls). <italic toggle="yes">P</italic><sub>original</sub> is a two-sided <italic toggle="yes">P</italic>-value for the burden association with the original continuous trait. Only genes with MAC<sub>case</sub> &#8805; 5 are shown. The top 5 FDR-significant genes with highest &#8722;log<sub>10</sub>
<italic toggle="yes">P</italic><sub>misaligned</sub> are labeled with gene symbol. Canonical and GEL genes are also labeled. The number of FDR-significant genes for each trait is indicated in parentheses in each subplot title. Protective misaligned status corresponds to low misaligned status and pathogenic misaligned status to high misaligned status, except for BMD and AAM, where the effects are flipped (protective=high misaligned, pathogenic=low misaligned).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="nihpp-2025.12.30.25343229v1-f0005.jpg"/></fig><table-wrap position="float" id="T2" orientation="portrait"><label>Table 1:</label><caption><title>REGENIE burden testing overview.</title><p id="P108">Burden testing with REGENIE was performed for both continuous and dichotomous trait misalignment testing. In continuous traits, it was only used for the exome-wide scan, while in dichotomous traits it was used for all three gene set categories. We tested both pLoF and putatively damaging missense variants for continuous traits, but only pLoF for dichotomous traits. Misalignment testing in continuous traits treated the misaligned status as a dichotomous variable, with misaligned individuals always encoded as a 1 and aligned as 0. Misalignment testing in dichotomous traits was performed on covariate-residualised PRS, a continuous variable. We use one-sided hypothesis tests throughout: for continuous traits, we always test for higher burden in misaligned individuals; for dichotomous traits, we test for a negative burden association in cases and a positive burden association in controls.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Trait type</th><th align="left" valign="top" rowspan="1" colspan="1">REGENIE used for misaligned phenotype testing in&#8230;</th><th align="left" valign="top" rowspan="1" colspan="1">Variant consequence burden masks</th><th colspan="2" align="left" valign="top" rowspan="1">Dependent variable in regression</th><th align="left" valign="top" rowspan="1" colspan="1">Hypothesized direction of burden effect</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="top" colspan="1">Continuous</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="bullet" id="L3"><list-item><p id="P109">Exome-wide scan</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="bullet" id="L11"><list-item><p id="P110">pLoF</p></list-item><list-item><p id="P111">Damaging missense</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">Misaligned status [encoding]</td><td align="left" valign="top" rowspan="1" colspan="1">High misaligned [1] vs. aligned [0]</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (OR&gt;1)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Low misaligned [1] vs. aligned [0]</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (OR&gt;1)</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">Dichotomous (disease status)</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="bullet" id="L5"><list-item><p id="P112">Canonical gene enrichment</p></list-item><list-item><p id="P113">GEL gene enrichment</p></list-item><list-item><p id="P114">Exome-wide scan</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">
<list list-type="bullet" id="L10"><list-item><p id="P115">pLoF</p></list-item></list>
</td><td rowspan="2" align="left" valign="top" colspan="1">PRS&#8242; (covariate-residualised PRS)</td><td align="left" valign="top" rowspan="1" colspan="1">PRS&#8242; in cases</td><td align="left" valign="top" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRS&#8242; in controls</td><td align="left" valign="top" rowspan="1" colspan="1">Positive</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T3" orientation="portrait"><label>Table 2:</label><caption><title>Monogenic disorder genes for continuous phenotypes.</title><p id="P116">Genes for each disorder are listed in alphabetical order. See <xref rid="S2" ref-type="sec">Methods</xref> for a description of how genes were selected.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Trait</th><th align="left" valign="top" rowspan="1" colspan="1">Disorder</th><th align="left" valign="top" rowspan="1" colspan="1">Effect direction of LoF</th><th align="left" valign="top" rowspan="1" colspan="1">Genes</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="top" colspan="1">Standing height</td><td rowspan="2" align="left" valign="top" colspan="1">Growth disorder</td><td align="left" valign="top" rowspan="1" colspan="1">Negative (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">EZH2, FBN1, NSD1</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">ACAN, FGFR3, IGF1, IGF1R, NPR2, SHOX</italic>
</td></tr><tr><td rowspan="2" align="left" valign="top" colspan="1">LDL cholesterol (LDL-C)</td><td rowspan="2" align="left" valign="top" colspan="1">Familial hypercholesterolemia</td><td align="left" valign="top" rowspan="1" colspan="1">Negative (protective)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">APOB, PCSK9</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Positive (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">LDLR</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Body mass index (BMI)</td><td align="left" valign="top" rowspan="1" colspan="1">Monogenic obesity</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">LEP, LEPR, MC4R, PCSK1, POMC</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intraocular pressure (IOP)</td><td align="left" valign="top" rowspan="1" colspan="1">Primary open-angle glaucoma</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">MYOC</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bone mineral density (BMD)</td><td align="left" valign="top" rowspan="1" colspan="1">Osteogenesis imperfecta</td><td align="left" valign="top" rowspan="1" colspan="1">Negative (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">COL1A1, COL1A2</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Glycated hemoglobin (HbA1C)</td><td align="left" valign="top" rowspan="1" colspan="1">Maturity-onset diabetes of the young (MODY)</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (pathogenic)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">GCK, HNF1A</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age at menopause (AAM)</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">Positive (protective)</td><td align="left" valign="top" rowspan="1" colspan="1">
<italic toggle="yes">CHEK2</italic>
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 3:</label><caption><p id="P117"><bold>Canonical monogenic genes tested for pLoF enrichment in disease traits</bold>.</p></caption><table frame="hsides" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1">Disease</th><th align="left" valign="middle" rowspan="1" colspan="1">Associated disorder</th><th align="left" valign="middle" rowspan="1" colspan="1">Effect of LoF</th><th align="left" valign="middle" rowspan="1" colspan="1">Genes</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" colspan="1">Type 2 diabetes (T2D)</td><td align="left" valign="middle" rowspan="1" colspan="1">Maturity-onset diabetes of the young (MODY)<sup><xref rid="R60" ref-type="bibr">60</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">Pathogenic</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">GCK</italic>, <italic toggle="yes">HNF1A</italic>, <italic toggle="yes">HNF4A</italic>, <italic toggle="yes">HNF1B</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">n/a</td><td align="left" valign="middle" rowspan="1" colspan="1">Protective<sup><xref rid="R61" ref-type="bibr">61</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">SLC30A8</italic>
</td></tr><tr><td rowspan="3" align="left" valign="middle" colspan="1">Coronary artery disease (CAD)</td><td rowspan="2" align="left" valign="middle" colspan="1">Familial hypercholesterolaemia</td><td align="left" valign="middle" rowspan="1" colspan="1">Protective<sup><xref rid="R62" ref-type="bibr">62</xref>&#8211;<xref rid="R64" ref-type="bibr">64</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">APOB</italic>, <italic toggle="yes">PCSK9</italic></td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathogenic<sup><xref rid="R65" ref-type="bibr">65</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">LDLR</italic>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Hereditary combined hypolipidemia<sup><xref rid="R66" ref-type="bibr">66</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">Protective</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">ANGPTL3</italic>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Osteoporosis (OP)</td><td align="left" valign="middle" rowspan="1" colspan="1">Osteogenesis imperfecta<sup><xref rid="R67" ref-type="bibr">67</xref></sup></td><td align="left" valign="middle" rowspan="1" colspan="1">Pathogenic</td><td align="left" valign="middle" rowspan="1" colspan="1"><italic toggle="yes">COL1A1</italic>,<italic toggle="yes">COL1A2</italic></td></tr></tbody></table></table-wrap></floats-group></article></pmc-articleset>